Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Pulmonary Medicine›Condition·Updated Jul 11, 2026·v1

Chronic Obstructive Pulmonary Disease

COPD is a leading cause of morbidity and mortality worldwide, diagnosed by spirometry and managed with smoking cessation, bronchodilators, exacerbation prevention strategies, and pulmonary rehabilitation. Triple therapy and biologics are reserved for high-risk patients with eosinophilic inflammation.

High Evidence682 references·12,264 words·50 min read·v1
COPDchronic obstructive pulmonary diseasepulmonary medicinespirometryexacerbationbronchodilatorsmoking cessationpulmonary rehabilitation

Quick Reference

RxDrug of choiceLAMA/LABA dual therapy (e.g., umeclidinium/vilanterol 62.5/25 μg once daily, indacaterol/glycopyrronium 110/50 μg once daily)
AltAlternativesTriple therapy (ICS/LAMA/LABA: fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 μg once daily, budesonide/glycopyrrolate/formoterol 320/18/9.6 μg twice daily); azithromycin 250 mg daily or 500 mg three times weekly; roflumilast 500 μg once daily; dupilumab 300 mg subcutaneously every 2 weeks; mepolizumab 100 mg subcutaneously every 4 weeks
⊘AvoidMaintenance oral corticosteroids, theophylline, benzodiazepines, beta-blockers without separate cardiovascular indication (metoprolol increased exacerbation hospitalizations)
DxTest of choicePost-bronchodilator spirometry (FEV1/FVC <0.70)
ScKey scoreGOLD ABCD assessment tool (symptom burden via mMRC or CAT + exacerbation history)
→When to referFrequent exacerbations despite triple therapy, evaluation for lung volume reduction or transplant, suspected alpha-1 antitrypsin deficiency, pulmonary rehabilitation, persistent hypercapnia for home NIV
COPD is diagnosed by spirometry; management focuses on smoking cessation, bronchodilation, exacerbation prevention, and pulmonary rehabilitation; triple therapy and biologics are reserved for high-risk patients with eosinophilic inflammation.
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable chronic respiratory disease characterized by persistent airflow limitation due to small airway disease and parenchymal destruction. It is the third leading cause of death worldwide, affecting over 390 million people. The diagnosis requires spirometric confirmation of a post-bronchodilator FEV1/FVC ratio <0.70. Management centers on smoking cessation, bronchodilator therapy (LAMA/LABA as first-line), exacerbation prevention, and pulmonary rehabilitation. Inhaled corticosteroids are reserved for patients with eosinophilic inflammation (blood eosinophils ≥300 cells/μL) and frequent exacerbations. Biologics (dupilumab, mepolizumab) are emerging options for refractory eosinophilic disease. Acute exacerbations are treated with bronchodilators, systemic corticosteroids for 5 days, antibiotics for purulent sputum, and noninvasive ventilation for hypercapnic respiratory failure. Prognosis is improved by early diagnosis, comprehensive pharmacotherapy, and non-pharmacologic interventions.

Overview and Recommendations

Background

  • •COPD, chronic obstructive pulmonary disease, is a common, preventable, and treatable chronic respiratory disease defined by persistent airflow limitation due to small airway disease and parenchymal destruction (emphysema). It affects approximately 392 million people globally (10.3% of adults aged 30-79) and is the third leading cause of death worldwide, causing 3.2 million deaths in 2015.
  • •The dominant risk factor is cigarette smoking (OR 3.2), but occupational exposures (14% attributable fraction), household air pollution from biomass, and ambient air pollution (PM2.5 per 5 μg/m³ increase OR 1.52) contribute significantly, especially in low- and middle-income countries where over 80% of cases reside.
  • •Genetic susceptibility amplifies risk: alpha-1 antitrypsin deficiency (Pi*ZZ genotype) causes early-onset emphysema; CFTR variants increase chronic bronchitis risk (OR 1.53); and a high polygenic risk score combined with smoking yields a hazard ratio of 11.62 for COPD.
  • •The disease encompasses several clinically relevant phenotypes: chronic bronchitis (cough and sputum ≥3 months/year for 2 years), emphysema (parenchymal destruction with reduced DLCO), frequent exacerbator (≥2 exacerbations/year), asthma-COPD overlap (variable obstruction with eosinophilic inflammation), and eosinophilic phenotype (blood eosinophils ≥300 cells/μL), each with distinct treatment implications.
  • •Pathophysiology involves chronic neutrophilic inflammation driven by inhaled particles, with protease-antiprotease imbalance (neutrophil elastase, MMP-9), oxidative stress, and cellular senescence. A subset (20-40%) exhibits type 2 inflammation with eosinophils, IL-5, IL-13, and epithelial alarmins, which is targetable by biologics.
  • •The natural history is characterized by accelerated FEV1 decline (mean 30-60 mL/year), with exacerbations, acute worsening of symptoms, accelerating progression and increasing mortality. The median survival after first hospitalization for COPD is 3.6 years, with mortality peaking in the first week post-exacerbation.

Evaluation

  • •Suspect COPD in any patient ≥40 years with exertional dyspnea, chronic cough, sputum production, and/or a history of smoking (≥10 pack-years) or other exposure to noxious particles (biomass, occupational dusts/fumes).
  • •Ask about the modified Medical Research Council (mMRC) dyspnea scale (grade ≥2 indicates significant symptoms), cough frequency, sputum volume and purulence, and number of exacerbations in the past year (including those requiring antibiotics, steroids, or hospitalization).
  • •Examine for signs of hyperinflation: barrel chest, hyperresonance to percussion, diminished breath sounds, prolonged expiration, and wheezing. In advanced disease, look for pursed-lip breathing, use of accessory muscles, tripod positioning, cyanosis, and signs of cor pulmonale (peripheral edema, elevated jugular venous pressure).
  • •Order post-bronchodilator spirometry as the gold-standard diagnostic test: a ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) <0.70 confirms persistent airflow limitation. Perform spirometry 15-30 minutes after 400 μg inhaled salbutamol.
  • •Grade severity by FEV1 percent predicted: GOLD 1 (≥80%), GOLD 2 (50-79%), GOLD 3 (30-49%), GOLD 4 (<30%). Also assess symptom burden using the COPD Assessment Test (CAT ≥10 indicates high symptoms) or mMRC (≥2).
  • •Classify exacerbation risk: high risk if ≥2 moderate exacerbations or ≥1 hospitalization for exacerbation in the prior year. This drives escalation to triple therapy and consideration of additional agents.
  • •Measure blood eosinophil count at least once to identify type 2 inflammation: ≥300 cells/μL predicts benefit from inhaled corticosteroids and eligibility for biologic therapy (dupilumab, mepolizumab).
  • •Order additional pulmonary function tests: lung volumes (body plethysmography) to detect hyperinflation (increased TLC, elevated RV/TLC ratio) and diffusing capacity for carbon monoxide (DLCO) to quantify gas transfer defect indicative of emphysema; DLCO <80% predicted is a strong predictor of mortality.
  • •Obtain high-resolution CT (HRCT) of the chest for phenotyping (emphysema, airway wall thickening, bronchiectasis), excluding alternative diagnoses (interstitial lung disease, bronchiectasis, lung cancer), and evaluating candidates for lung volume reduction.
  • •Test all patients for alpha-1 antitrypsin deficiency at diagnosis: measure serum AAT level; if <23 μmol/L, proceed to genotyping. Severe deficiency (AAT <11 μmol/L) qualifies for augmentation therapy.
  • •Order arterial blood gas if FEV1 <50% predicted or if signs of respiratory failure (cyanosis, confusion, use of accessory muscles): chronic hypoxemia (PaO2 <60 mmHg) and/or hypercapnia (PaCO2 >45 mmHg) guide long-term oxygen therapy and home NIV.
  • •Evaluate for common comorbidities: cardiovascular disease (ECG, echocardiogram if suspected), osteoporosis (DEXA scan if risk factors), anxiety and depression (screening questionnaires), and lung cancer (low-dose CT if eligible per screening criteria).
  • •For acute exacerbation diagnosis, use clinical criteria: increased dyspnea, increased sputum volume, and/or sputum purulence. Point-of-care CRP >20 mg/L supports antibiotic use. The Roth score (≥9.95 seconds) and Dyspnea Severity Score (≤5) can aid safe discharge decisions from the emergency department.
  • •Consider alternative diagnoses if atypical features: asthma (variable obstruction, younger age, atopy), bronchiectasis (copious purulent sputum, clubbing), interstitial lung disease (crackles, restrictive pattern), heart failure (orthopnea, edema, BNP elevation), tuberculosis (endemic areas, hemoptysis).

Management

  • •Initiate smoking cessation for all patients who smoke: combine pharmacotherapy (varenicline 1 mg twice daily, bupropion 150 mg twice daily, or nicotine replacement therapy) with behavioral counseling. Cytisinicline 3 mg three times daily for 6-12 weeks is an alternative.
  • •Start first-line maintenance therapy with a long-acting muscarinic antagonist (LAMA) / long-acting β2-agonist (LABA) combination for symptomatic patients (mMRC ≥2 or CAT ≥10): umeclidinium/vilanterol 62.5/25 μg once daily, or indacaterol/glycopyrronium 110/50 μg once daily, or tiotropium/olodaterol 2.5/2.5 μg two puffs once daily.
  • •For patients with low symptom burden (mMRC 0-1, CAT <10) and low exacerbation risk, LAMA or LABA monotherapy is acceptable: tiotropium 18 μg once daily or indacaterol 75 μg once daily.
  • •Escalate to triple therapy (ICS/LAMA/LABA) in patients with ≥1 exacerbation in the past year despite dual bronchodilation, especially if blood eosinophils ≥300 cells/μL: fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 μg once daily, or budesonide/glycopyrrolate/formoterol 320/18/9.6 μg twice daily. Triple therapy reduces moderate/severe exacerbations by 15-25% versus dual therapy and, in ETHOS, reduced all-cause mortality (HR 0.51).
  • •For patients with persistent exacerbations despite triple therapy and blood eosinophils ≥300 cells/μL, add a biologic: dupilumab 300 mg subcutaneously every 2 weeks (reduces exacerbations by 30%, improves FEV1 by 83 mL) or mepolizumab 100 mg subcutaneously every 4 weeks (reduces exacerbations by 21%).
  • •For frequent exacerbators (≥2 exacerbations/year) despite optimal inhaled therapy, consider add-on azithromycin 250 mg daily or 500 mg three times weekly. Monitor QTc interval and hearing; hearing decrements occur in 25% of patients.
  • •For patients with chronic bronchitis phenotype and frequent exacerbations, consider roflumilast 500 μg once daily (PDE4 inhibitor). Monitor for weight loss and gastrointestinal side effects; reduces exacerbations by 12-16%.
  • •For acute exacerbation: administer short-acting bronchodilators, albuterol 2.5 mg via nebulizer every 20 minutes for three doses, then every 2-4 hours as needed. Add ipratropium 0.5 mg if inadequate response.
  • •Give systemic corticosteroids: prednisolone 30-40 mg orally once daily for 5 days (or IV methylprednisolone equivalent). Do not extend beyond 5 days; longer courses increase hyperglycemia risk (NNH=5).
  • •Start antibiotics only if sputum is purulent or CRP >20 mg/L: amoxicillin-clavulanate 875/125 mg twice daily for 5 days, or azithromycin 500 mg on day 1 then 250 mg daily for 4 days if penicillin-allergic.
  • •Provide supplemental oxygen to target SpO2 88-92% during exacerbation. Use Venturi mask (24-28% FiO2). Avoid hyperoxia (SpO2 >92%) to reduce risk of hypercapnic respiratory failure.
  • •Initiate noninvasive ventilation (NIV) if pH <7.35 and PaCO2 >45 mmHg despite medical therapy: BiPAP mode, start IPAP 10-12 cmH2O, EPAP 4-5 cmH2O, titrate to tidal volume 6-8 mL/kg and respiratory rate <25/min. Recheck ABG after 1-2 hours; if no improvement, escalate to invasive ventilation.
  • •For severe exacerbation with NIV failure (no pH improvement), hemodynamic instability, or altered mental status, proceed to invasive mechanical ventilation. Use lung-protective ventilation strategies.
  • •Prescribe long-term oxygen therapy (LTOT) for patients with chronic severe resting hypoxemia: PaO2 ≤55 mmHg or SpO2 ≤88% on room air. Use at least 15 hours/day to improve survival.
  • •Consider nocturnal NIV for patients with chronic stable hypercapnia (PaCO2 ≥52 mmHg) after optimization of medical therapy. High-intensity NIV targeted to reduce PaCO2 by ≥20% improves 1-year survival (NNT=5).
  • •Refer all symptomatic patients to pulmonary rehabilitation: improves exercise capacity (6-minute walk distance +57 m), reduces hospital readmissions (OR 0.48), and improves quality of life. Start within 3 weeks of exacerbation discharge.
  • •Ensure up-to-date vaccinations: influenza vaccine annually, pneumococcal vaccine (PCV13 followed by PPSV23 at least 8 weeks later), COVID-19 vaccine, and consider pertussis and RSV vaccines per local guidelines.
  • •Avoid: maintenance oral corticosteroids (poor risk-benefit), theophylline (narrow therapeutic window), benzodiazepines (respiratory depression), and beta-blockers without a separate cardiovascular indication (metoprolol increased exacerbation hospitalizations in BLOCK COPD trial).
  • •Refer for bronchoscopic lung volume reduction (endobronchial valves) in patients with heterogeneous emphysema, hyperinflation (RV >175% predicted), and no collateral ventilation. Zephyr valves improved FEV1 by 106 mL, 6MWD by 39 m, and SGRQ by 7 points; pneumothorax risk 26.6%.
  • •Refer for lung volume reduction surgery or lung transplantation in selected patients with advanced disease (GOLD 3-4, BODE index 7-10, progressive despite maximal therapy).

Board Review — High Yield

  • •GOLD criteria, COPD diagnosis requires post-bronchodilator FEV1/FVC <0.70.
  • •FLAME trial, LAMA/LABA (indacaterol/glycopyrronium) superior to ICS/LABA for exacerbation prevention.
  • •IMPACT/ETHOS trials, Triple therapy reduces exacerbations and, in ETHOS, all-cause mortality vs LAMA/LABA.
  • •BODE index, Multidimensional prognostic score (BMI, Obstruction, Dyspnea, Exercise) predicts mortality better than FEV1 alone.
  • •Blood eosinophils, ≥300 cells/μL predicts ICS benefit and eligibility for biologics (dupilumab, mepolizumab).
  • •NIV in acute exacerbation, Reduces intubation (RR 0.36) and mortality (RR 0.46) when pH <7.35 and PaCO2 >45.
  • •Azithromycin, Reduces exacerbations in frequent exacerbators; monitor QTc and hearing.
  • •Alpha-1 antitrypsin deficiency, Test all COPD patients at diagnosis; severe deficiency (AAT <11 μmol/L) qualifies for augmentation therapy.
  • •Pulmonary rehabilitation, Reduces hospital readmissions (OR 0.48) and improves exercise capacity.
  • •Smoking cessation, Single most effective intervention; pharmacotherapy + counseling triples quit rates.

Deep Dive — Evidence Details

References

  1. [1]

    Rochester CL, Alison JA, Carlin B et al.. “Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2023). PMID: 37581410 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  2. [2]

    Spruit MA, Singh SJ, Garvey C et al.. “An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation.” American journal of respiratory and critical care medicine (2013). PMID: 24127811 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  3. [3]

    Vogelmeier CF, Criner GJ, Martinez FJ et al.. “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.” American journal of respiratory and critical care medicine (2017). PMID: 28128970 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
  4. [4]

    Macrea M, Oczkowski S, Rochwerg B et al.. “Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2020). PMID: 32795139 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications
  5. [5]

    Wedzicha JA, Miravitlles M, Hurst JR et al.. “Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.” The European respiratory journal (2017). PMID: 28298398 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  6. [6]

    Bakke PS, Rönmark E, Eagan T et al.. “Recommendations for epidemiological studies on COPD.” The European respiratory journal (2011). PMID: 22130763 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature
  7. [7]

    Bourbeau J, Bhutani M, Hernandez P et al.. “2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD.” Chest (2023). PMID: 37690008 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  8. [8]

    Hernandez P, Bossé Y, Bush P et al.. “Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline.” Chest (2025). PMID: 39880301 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
  9. [9]

    Uzun S, Djamin RS, Kluytmans JA et al.. “Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.” The Lancet. Respiratory medicine (2014). PMID: 24746000 ↗

    L1RCTCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  10. [10]

    Hardinge M, Annandale J, Bourne S et al.. “British Thoracic Society guidelines for home oxygen use in adults.” Thorax (2015). PMID: 25870317 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue
  11. [11]

    Halbert RJ, Natoli JL, Gano A et al.. “Global burden of COPD: systematic review and meta-analysis.” The European respiratory journal (2006). PMID: 16611654 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature
  12. [12]

    Sciurba FC, Criner GJ, Christenson SA et al.. “Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.” The New England journal of medicine (2025). PMID: 40305712 ↗

    L1RCTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  13. [13]

    Pavord ID, Chanez P, Criner GJ et al.. “Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.” The New England journal of medicine (2017). PMID: 28893134 ↗

    L1RCTCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  14. [14]

    Han MK, Muellerova H, Curran-Everett D et al.. “GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.” The Lancet. Respiratory medicine (2012). PMID: 24321803 ↗

    L2TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature
  15. [15]

    Adeloye D, Song P, Zhu Y et al.. “Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis.” The Lancet. Respiratory medicine (2022). PMID: 35279265 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  16. [16]

    Karloh M, Fleig Mayer A, Maurici R et al.. “The COPD Assessment Test: What Do We Know So Far?: A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients Into GOLD Stages.” Chest (2016). PMID: 26513112 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  17. [17]

    Postma DS, Brightling C, Baldi S et al.. “Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.” The Lancet. Respiratory medicine (2019). PMID: 30876830 ↗

    L2COHORTCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  18. [18]

    Gedebjerg A, Szépligeti SK, Wackerhausen LH et al.. “Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study.” The Lancet. Respiratory medicine (2018). PMID: 29331311 ↗

    L2COHORTCited in: 1. Definition, Classification and Nomenclature, 10. Complications
  19. [19]

    Rhee CK, Chau NQ, Yunus F et al.. “Management of COPD in Asia: A position statement of the Asian Pacific Society of Respirology.” Respirology (Carlton, Vic.) (2019). PMID: 31276272 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
  20. [20]

    Kennedy CC, Novotny PJ, LeBrasseur NK et al.. “Frailty and Clinical Outcomes in Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2019). PMID: 30433830 ↗

    L3RCTCited in: 1. Definition, Classification and Nomenclature
  21. [21]

    Mathioudakis AG, Moberg M, Janner J et al.. “Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials.” ERJ open research (2019). PMID: 31111041 ↗

    L1RCTCited in: 1. Definition, Classification and Nomenclature
  22. [22]

    Singh D, Han MK, Bhatt SP et al.. “Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?” American journal of respiratory and critical care medicine (2025). PMID: 39680953 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 11. Prognosis and Natural History
  23. [23]

    Kim V, Criner GJ. “Chronic bronchitis and chronic obstructive pulmonary disease.” American journal of respiratory and critical care medicine (2012). PMID: 23204254 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History
  24. [24]

    Barnes PJ, Baker J, Donnelly LE. “Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases.” American journal of respiratory and critical care medicine (2019). PMID: 30860857 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, History and Evolution of Treatment
  25. [25]

    Bhatt SP, Nakhmani A, Fortis S et al.. “FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2023). PMID: 37339502 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  26. [26]

    Adir Y, Humbert M, Chaouat A. “Sleep-related breathing disorders and pulmonary hypertension.” The European respiratory journal (2021). PMID: 32747397 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  27. [27]

    Brightling C, Greening N. “Airway inflammation in COPD: progress to precision medicine.” The European respiratory journal (2019). PMID: 31073084 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  28. [28]

    Zhou JS, Li ZY, Xu XC et al.. “Cigarette smoke-initiated autoimmunity facilitates sensitisation to elastin-induced COPD-like pathologies in mice.” The European respiratory journal (2020). PMID: 32366484 ↗

    L5OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 11. Prognosis and Natural History
  29. [29]

    Thomson NC. “Asthma and smoking-induced airway disease without spirometric COPD.” The European respiratory journal (2017). PMID: 28461294 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
  30. [30]

    Polverino E, Dimakou K, Hurst J et al.. “The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.” The European respiratory journal (2018). PMID: 30049739 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  31. [31]

    Zhang M, Yan R, Lou L et al.. “Effects of Concurrent Strength and Aerobic Exercise Training on Cognitive Health in Adults With Physiological or Neurocognitive Disorders: Systematic Review With Meta-analysis of Randomized Controlled Trials.” Sports health (2026). PMID: 42358083 ↗

    L1SR_MA_RCTCited in: 1. Definition, Classification and Nomenclature
  32. [32]

    . “Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.” The Lancet. Respiratory medicine (2017). PMID: 28822787 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  33. [33]

    Aung HWW, Vermeersch K, McAuley HJC et al.. “Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) model.” The Lancet. Respiratory medicine (2025). PMID: 41314222 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 6. Severity, Staging and Risk Stratification
  34. [34]

    Du Berry C, Gray DM, Bates A et al.. “Trajectories of prematurity-associated lung disease: lifelong lung health.” The Lancet. Respiratory medicine (2025). PMID: 41319659 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature
  35. [35]

    Dilektasli AG, Porszasz J, Casaburi R et al.. “A Novel Spirometric Measure Identifies Mild COPD Unidentified by Standard Criteria.” Chest (2016). PMID: 27452770 ↗

    L4OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
  36. [36]

    Hurst JR, Vestbo J, Anzueto A et al.. “Susceptibility to exacerbation in chronic obstructive pulmonary disease.” The New England journal of medicine (2010). PMID: 20843247 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature
  37. [37]

    Woodruff PG, Barr RG, Bleecker E et al.. “Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.” The New England journal of medicine (2016). PMID: 27168432 ↗

    L4OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  38. [38]

    Washko GR, Hunninghake GM, Fernandez IE et al.. “Lung volumes and emphysema in smokers with interstitial lung abnormalities.” The New England journal of medicine (2011). PMID: 21388308 ↗

    L4OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  39. [39]

    David B, Bafadhel M, Koenderman L et al.. “Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait.” Thorax (2020). PMID: 33122447 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism
  40. [40]

    Çolak Y, Afzal S, Marott JL et al.. “Type-2 inflammation and lung function decline in chronic airway disease in the general population.” Thorax (2024). PMID: 38195642 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, 11. Prognosis and Natural History
  41. [41]

    Donaldson GC, Wedzicha JA. “COPD exacerbations .1: Epidemiology.” Thorax (2006). PMID: 16443707 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
  42. [42]

    Stoleriu MG, Ansari M, Strunz M et al.. “COPD basal cells are primed towards secretory to multiciliated cell imbalance driving increased resilience to environmental stressors.” Thorax (2024). PMID: 38286613 ↗

    L5OTHERCited in: 1. Definition, Classification and Nomenclature
  43. [43]

    Marsh SE, Travers J, Weatherall M et al.. “Proportional classifications of COPD phenotypes.” Thorax (2008). PMID: 18728201 ↗

    L4OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  44. [44]

    Postma DS, Brusselle G, Bush A et al.. “I have taken my umbrella, so of course it does not rain.” Thorax (2011). PMID: 21873323 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  45. [45]

    Sapey E, Bafadhel M, Bolton CE et al.. “Building toolkits for COPD exacerbations: lessons from the past and present.” Thorax (2019). PMID: 31273049 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
  46. [46]

    Vásquez-Andrade R, Alcaraz-Serrano V, Buekers J et al.. “Development of an artificial intelligence prediction model for moderate-to-severe COPD exacerbations using continuous multiple unobtrusive sensors: protocol of a multicentre prospective observational study.” BMJ open respiratory research (2026). PMID: 42242832 ↗

    L5TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature
  47. [47]

    Wan X, Du Y, Zhang C et al.. “Outcomes of pulmonary rehabilitation in older adults with chronic obstructive pulmonary disease: a systematic review.” BMC geriatrics (2026). PMID: 42387413 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  48. [48]

    Deng HY, Ran XY, Qian R. “Cardiometabolic risk and mortality in PRISm versus COPD: a systematic review and meta-analysis.” NPJ primary care respiratory medicine (2026). PMID: 42324268 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature
  49. [49]

    de Victoria Carazo JM, Guirao Arrabal E, Montero-Alonso MÁ et al.. “Incidence, mortality and risk factors in COVID-19-associated pulmonary aspergillosis (CAPA): an umbrella review and meta-meta-analyses (2020-2025).” Respiratory medicine (2026). PMID: 42302999 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature
  50. [50]

    Xie S, Xie M, Li G et al.. “The relationship between traditional Chinese medicine constitution and indexes in chronic obstructive pulmonary disease patients: a systematic review and network meta-analysis.” Frontiers in medicine (2026). PMID: 42254404 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature
  51. [51]

    Calle Rubio M, López-Campos JL, Casas Maldonado F et al.. “Spanish Clinical Practice Guidelines for the Diagnosis and Management of Alpha-1 Antitrypsin Deficiency: 2026 Update.” Archivos de bronconeumologia (2026). PMID: 42392940 ↗

    L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
  52. [52]

    Donovan T, Milan SJ, Wang R et al.. “Anti-IL-5 therapies for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2020). PMID: 33295032 ↗

    L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
  53. [53]

    Lenferink A, Brusse-Keizer M, van der Valk PD et al.. “Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2017). PMID: 28777450 ↗

    L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 13. Prevention, Screening & Surveillance
  54. [54]

    Janjua S, Banchoff E, Threapleton CJ et al.. “Digital interventions for the management of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2021). PMID: 33871065 ↗

    L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  55. [55]

    Ram FS, Rodriguez-Roisin R, Granados-Navarrete A et al.. “Antibiotics for exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2006). PMID: 16625602 ↗

    L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
  56. [56]

    Ram FS, Rodriguez-Roisin R, Granados-Navarrete A et al.. “WITHDRAWN: Antibiotics for exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2011). PMID: 21249661 ↗

    L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment
  57. [57]

    Kopsaftis Z, Carson-Chahhoud KV, Austin MA et al.. “Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2020). PMID: 31934729 ↗

    L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  58. [58]

    Usmani ZA, Carson KV, Cheng JN et al.. “Pharmacological interventions for the treatment of anxiety disorders in chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2011). PMID: 22071851 ↗

    L1SR_OBSCited in: 1. Definition, Classification and Nomenclature
  59. [59]

    Kew KM, Seniukovich A. “Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2014). PMID: 24615270 ↗

    L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  60. [60]

    Pu J, Yu M, Wei H et al.. “Clinical and prognostic differences in mild to moderate AECOPD with and without emphysema: a 3-year multicenter prospective study.” Frontiers in medicine (2026). PMID: 42422826 ↗

    L2COHORTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History
  61. [61]

    MacLeod M, Papi A, Contoli M et al.. “Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact.” Respirology (Carlton, Vic.) (2021). PMID: 33893708 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  62. [62]

    Lange P, Ahmed E, Lahmar ZM et al.. “Natural history and mechanisms of COPD.” Respirology (Carlton, Vic.) (2021). PMID: 33506971 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History
  63. [63]

    Sheikh K, Coxson HO, Parraga G. “This is what COPD looks like.” Respirology (Carlton, Vic.) (2015). PMID: 26333307 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  64. [64]

    Cobb K, Kenyon J, Lu J et al.. “COPD is associated with increased cardiovascular disease risk independent of phenotype.” Respirology (Carlton, Vic.) (2024). PMID: 39019777 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature
  65. [65]

    Zeng G, Sun B, Zhong N. “Non-smoking-related chronic obstructive pulmonary disease: a neglected entity?” Respirology (Carlton, Vic.) (2012). PMID: 22845669 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism
  66. [66]

    Margaritopoulos GA, Harari S, Caminati A et al.. “Smoking-related idiopathic interstitial pneumonia: A review.” Respirology (Carlton, Vic.) (2015). PMID: 26138798 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  67. [67]

    Tho NV, Park HY, Nakano Y. “Asthma-COPD overlap syndrome (ACOS): A diagnostic challenge.” Respirology (Carlton, Vic.) (2015). PMID: 26450153 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  68. [68]

    Labaki WW, Han MK. “Improving Detection of Early Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2018). PMID: 30759006 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
  69. [69]

    Shin S, Poliwoda J, Whitmore GA et al.. “Cough in Adults with Undiagnosed Respiratory Symptoms.” Annals of the American Thoracic Society (2025). PMID: 40788604 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
  70. [70]

    Garudadri S, Woodruff PG. “Targeting Chronic Obstructive Pulmonary Disease Phenotypes, Endotypes, and Biomarkers.” Annals of the American Thoracic Society (2018). PMID: 30758998 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature
  71. [71]

    Bhat TA, Panzica L, Kalathil SG et al.. “Immune Dysfunction in Patients with Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2015). PMID: 26595735 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification
  72. [72]

    Bui KL, Nyberg A, Maltais F et al.. “Functional Tests in Chronic Obstructive Pulmonary Disease, Part 2: Measurement Properties.” Annals of the American Thoracic Society (2017). PMID: 28244801 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature
  73. [73]

    Mall MA. “Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2016). PMID: 27115954 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature
  74. [74]

    Hiemstra PS. “Altered macrophage function in chronic obstructive pulmonary disease.” Annals of the American Thoracic Society (2013). PMID: 24313770 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature
  75. [75]

    Øie MR, Dahlslett SB, Sue-Chu M et al.. “Rhinosinusitis without nasal polyps in COPD.” ERJ open research (2020). PMID: 32665943 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  76. [76]

    Celli BR, Agustí A. “COPD: time to improve its taxonomy?” ERJ open research (2018). PMID: 29707563 ↗

    L5OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  77. [77]

    Cosío BG, Casanova C, Soler-Cataluña JJ et al.. “Unravelling young COPD and pre-COPD in the general population.” ERJ open research (2023). PMID: 36814553 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  78. [78]

    Divo MJ, Marin Oto M, Casanova Macario C et al.. “Somatotypes trajectories during adulthood and their association with COPD phenotypes.” ERJ open research (2020). PMID: 32963991 ↗

    L4OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  79. [79]

    Bhattarai P, Lu W, Gaikwad AV et al.. “Arterial remodelling in smokers and in patients with small airway disease and COPD: implications for lung physiology and early origins of pulmonary hypertension.” ERJ open research (2022). PMID: 36478915 ↗

    L3OTHERCited in: 1. Definition, Classification and Nomenclature, 10. Complications
  80. [80]

    Reddel HK, Gerhardsson de Verdier M, Agustí A et al.. “Prospective observational study in patients with obstructive lung disease: NOVELTY design.” ERJ open research (2019). PMID: 30723727 ↗

    L5OTHERCited in: 1. Definition, Classification and Nomenclature
  81. [81]

    Waeijen-Smit K, Jacobsen PA, Houben-Wilke S et al.. “All-cause admissions following a first ever exacerbation-related hospitalisation in COPD.” ERJ open research (2023). PMID: 36605904 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature
  82. [82]

    Yousuf AJ, Mohammed S, Carr L et al.. “Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.” The Lancet. Respiratory medicine (2022). PMID: 35339234 ↗

    L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  83. [83]

    Rabe KF, Watz H, Baraldo S et al.. “Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.” The Lancet. Respiratory medicine (2018). PMID: 30224319 ↗

    L1RCTCited in: 2. Pathophysiology and Mechanism
  84. [84]

    Brightling CE, Bleecker ER, Panettieri RA et al.. “Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.” The Lancet. Respiratory medicine (2014). PMID: 25208464 ↗

    L1RCTCited in: 2. Pathophysiology and Mechanism
  85. [85]

    Zheng JP, Wen FQ, Bai CX et al.. “Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.” The Lancet. Respiratory medicine (2014). PMID: 24621680 ↗

    L1RCTCited in: 2. Pathophysiology and Mechanism
  86. [86]

    Chalmers JD, Chotirmall SH. “Bronchiectasis: new therapies and new perspectives.” The Lancet. Respiratory medicine (2018). PMID: 29478908 ↗

    L2SR_OBSCited in: 2. Pathophysiology and Mechanism, 11. Prognosis and Natural History
  87. [87]

    Shoemark A, Johnson ED, Shuttleworth M et al.. “Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study.” The Lancet. Respiratory medicine (2026). PMID: 42044645 ↗

    L2COHORTCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
  88. [88]

    Mohamed MMG, Kamel G, Charbek E. “Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials.” Annals of the American Thoracic Society (2025). PMID: 39589286 ↗

    L1SR_MA_RCTCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History
  89. [89]

    Daynes E, Greening N, Sidiqqui S et al.. “A randomised controlled trial to investigate the use of high-frequency airway oscillations as training to improve dyspnoea in COPD.” ERJ open research (2019). PMID: 31367635 ↗

    L5RCTCited in: 2. Pathophysiology and Mechanism
  90. [90]

    Rabe KF, Rennard S, Martinez FJ et al.. “Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook.” American journal of respiratory and critical care medicine (2023). PMID: 37348121 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  91. [91]

    Barnes PJ. “Theophylline.” American journal of respiratory and critical care medicine (2013). PMID: 23672674 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
  92. [92]

    Verleden SE, Hendriks JMH, Snoeckx A et al.. “Small Airway Disease in Pre-Chronic Obstructive Pulmonary Disease with Emphysema: A Cross-Sectional Study.” American journal of respiratory and critical care medicine (2024). PMID: 38055196 ↗

    L3OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  93. [93]

    Maltais F, Decramer M, Casaburi R et al.. “An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.” American journal of respiratory and critical care medicine (2014). PMID: 24787074 ↗

    L1REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  94. [94]

    Bafadhel M, McKenna S, Terry S et al.. “Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.” American journal of respiratory and critical care medicine (2011). PMID: 21680942 ↗

    L2OTHERCited in: 2. Pathophysiology and Mechanism
  95. [95]

    Celli BR, Christenson SA, Rabe KF et al.. “Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy.” American journal of respiratory and critical care medicine (2025). PMID: 39938077 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  96. [96]

    Ryan EM, Sadiku P, Coelho P et al.. “NRF2 Activation Reprograms Defects in Oxidative Metabolism to Restore Macrophage Function in Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2023). PMID: 36724365 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  97. [97]

    Booth S, Hsieh A, Mostaco-Guidolin L et al.. “A Single-Cell Atlas of Small Airway Disease in Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study.” American journal of respiratory and critical care medicine (2023). PMID: 37406359 ↗

    L3OTHERCited in: 2. Pathophysiology and Mechanism
  98. [98]

    Strickson S, Houslay KF, Negri VA et al.. “Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex.” The European respiratory journal (2023). PMID: 37442582 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  99. [99]

    Barnes PJ, Celli BR. “Systemic manifestations and comorbidities of COPD.” The European respiratory journal (2009). PMID: 19407051 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
  100. [100]

    Meiners S, Eickelberg O, Königshoff M. “Hallmarks of the ageing lung.” The European respiratory journal (2015). PMID: 25657021 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors
  101. [101]

    Mall MA, Hartl D. “CFTR: cystic fibrosis and beyond.” The European respiratory journal (2014). PMID: 24925916 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  102. [102]

    Dempsey JA, Smith CA. “Pathophysiology of human ventilatory control.” The European respiratory journal (2014). PMID: 24925922 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  103. [103]

    Burtin C, Decramer M, Gosselink R et al.. “Rehabilitation and acute exacerbations.” The European respiratory journal (2011). PMID: 21719481 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  104. [104]

    Doyle AD, Mukherjee M, LeSuer WE et al.. “Eosinophil-derived IL-13 promotes emphysema.” The European respiratory journal (2019). PMID: 30728205 ↗

    L4OTHERCited in: 2. Pathophysiology and Mechanism
  105. [105]

    Yang IA, Jenkins CR, Salvi SS. “Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment.” The Lancet. Respiratory medicine (2022). PMID: 35427530 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation
  106. [106]

    Agustí A, Melén E, DeMeo DL et al.. “Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan.” The Lancet. Respiratory medicine (2022). PMID: 35427533 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation
  107. [107]

    Budden KF, Shukla SD, Rehman SF et al.. “Functional effects of the microbiota in chronic respiratory disease.” The Lancet. Respiratory medicine (2019). PMID: 30975495 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  108. [108]

    Cho MH, Hobbs BD, Silverman EK. “Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder.” The Lancet. Respiratory medicine (2022). PMID: 35427534 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  109. [109]

    Balbirsingh V, Mohammed AS, Turner AM et al.. “Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review.” Thorax (2022). PMID: 35772939 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
  110. [110]

    O'Donnell DE, Parker CM. “COPD exacerbations . 3: Pathophysiology.” Thorax (2006). PMID: 16565268 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, History and Evolution of Treatment, 10. Complications
  111. [111]

    Naesilla N, Quint JK, Zuber V. “Understanding the bidirectional relationship between chronic respiratory disease and cardiovascular disease using genetic evidence.” Thorax (2026). PMID: 41241414 ↗

    L2OTHERCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
  112. [112]

    Ng-Blichfeldt JP, Gosens R, Dean C et al.. “Regenerative pharmacology for COPD: breathing new life into old lungs.” Thorax (2019). PMID: 30940772 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  113. [113]

    Franssen FM, O'Donnell DE, Goossens GH et al.. “Obesity and the lung: 5. Obesity and COPD.” Thorax (2008). PMID: 19020276 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  114. [114]

    Paredi P, Barnes PJ. “The airway vasculature: recent advances and clinical implications.” Thorax (2009). PMID: 19401490 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  115. [115]

    Vestbo J, Hogg JC. “Convergence of the epidemiology and pathology of COPD.” Thorax (2005). PMID: 16227325 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  116. [116]

    Persson C, Uller L. “Transepithelial exit of leucocytes: inflicting, reflecting or resolving airway inflammation?” Thorax (2010). PMID: 20688768 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 13. Prevention, Screening & Surveillance
  117. [117]

    Liu X, Yu X, Yang Q et al.. “Association of asthma and COPD with pertussis risk: A systematic review and meta-analysis.” Respiratory medicine (2026). PMID: 42309234 ↗

    L2SR_OBSCited in: 2. Pathophysiology and Mechanism, 13. Prevention, Screening & Surveillance
  118. [118]

    Holland AE, Hill CJ, Jones AY et al.. “Breathing exercises for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2012). PMID: 23076942 ↗

    L1SR_OBSCited in: 2. Pathophysiology and Mechanism
  119. [119]

    Chong J, Leung B, Poole P. “Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2013). PMID: 24190161 ↗

    L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 13. Prevention, Screening & Surveillance
  120. [120]

    Janjua S, Fortescue R, Poole P. “Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2020). PMID: 32356609 ↗

    L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications, 13. Prevention, Screening & Surveillance
  121. [121]

    Chong J, Leung B, Poole P. “Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2017). PMID: 28922692 ↗

    L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 13. Prevention, Screening & Surveillance
  122. [122]

    Chong J, Poole P, Leung B et al.. “Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2011). PMID: 21563134 ↗

    L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 13. Prevention, Screening & Surveillance
  123. [123]

    Struik FM, Lacasse Y, Goldstein R et al.. “Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2013). PMID: 23766138 ↗

    L1SR_OBSCited in: 2. Pathophysiology and Mechanism
  124. [124]

    Huang T, Sun R, Sun Z et al.. “Immune-inflammatory vulnerability index for risk stratification in older adults with acute exacerbations of COPD: a prospective cohort study.” BMC geriatrics (2026). PMID: 42374311 ↗

    L2COHORTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
  125. [125]

    Adler R, Kozlov M, Kriplani K et al.. “IL-17 inhibitor therapy and risk of chronic obstructive pulmonary disease and related pulmonary outcomes in patients with psoriasis: A real-world cohort study.” Respiratory medicine (2026). PMID: 42314776 ↗

    L2COHORTCited in: 2. Pathophysiology and Mechanism, 10. Complications
  126. [126]

    Thawanaphong S, Nair P. “Contemporary Concise Review 2024: Chronic Obstructive Pulmonary Disease.” Respirology (Carlton, Vic.) (2025). PMID: 40437348 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
  127. [127]

    Murgia N, Gambelunghe A. “Occupational COPD-The most under-recognized occupational lung disease?” Respirology (Carlton, Vic.) (2022). PMID: 35513770 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
  128. [128]

    O'Donnell DE, Neder JA, Elbehairy AF. “Physiological impairment in mild COPD.” Respirology (Carlton, Vic.) (2015). PMID: 26333038 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  129. [129]

    Shukla SD, Walters EH, Simpson JL et al.. “Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease.” Respirology (Carlton, Vic.) (2019). PMID: 31663668 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
  130. [130]

    Jones B, Donovan C, Liu G et al.. “Animal models of COPD: What do they tell us?” Respirology (Carlton, Vic.) (2016). PMID: 27731525 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification
  131. [131]

    Leung JM, Tiew PY, Mac Aogáin M et al.. “The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD.” Respirology (Carlton, Vic.) (2017). PMID: 28342288 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  132. [132]

    Blanco I, Piccari L, Barberà JA. “Pulmonary vasculature in COPD: The silent component.” Respirology (Carlton, Vic.) (2016). PMID: 27028849 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 10. Complications
  133. [133]

    Whitsett JA. “Airway Epithelial Differentiation and Mucociliary Clearance.” Annals of the American Thoracic Society (2018). PMID: 30431340 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation
  134. [134]

    Lee AS, Lee JS, He Z et al.. “Reflux-Aspiration in Chronic Lung Disease.” Annals of the American Thoracic Society (2020). PMID: 31697575 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation
  135. [135]

    Bush A. “Lung Development and Aging.” Annals of the American Thoracic Society (2016). PMID: 28005431 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 11. Prognosis and Natural History
  136. [136]

    Ward SA, Grocott MPW, Levett DZH. “Exercise Testing, Supplemental Oxygen, and Hypoxia.” Annals of the American Thoracic Society (2017). PMID: 28590162 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue
  137. [137]

    MacNee W. “Is Chronic Obstructive Pulmonary Disease an Accelerated Aging Disease?” Annals of the American Thoracic Society (2016). PMID: 28005421 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  138. [138]

    Lomas DA. “Does Protease-Antiprotease Imbalance Explain Chronic Obstructive Pulmonary Disease?” Annals of the American Thoracic Society (2016). PMID: 27115947 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  139. [139]

    Ritchie AI, Farne HA, Singanayagam A et al.. “Pathogenesis of Viral Infection in Exacerbations of Airway Disease.” Annals of the American Thoracic Society (2015). PMID: 26595727 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  140. [140]

    Kelsen SG. “The Unfolded Protein Response in Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2016). PMID: 27115948 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  141. [141]

    Fieldes M, Bourguignon C, Assou S et al.. “Targeted therapy in eosinophilic chronic obstructive pulmonary disease.” ERJ open research (2021). PMID: 33855061 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  142. [142]

    Baines KJ, Wright TK, Gibson PG et al.. “Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD.” ERJ open research (2018). PMID: 30406125 ↗

    L1OTHERCited in: 2. Pathophysiology and Mechanism
  143. [143]

    Zaigham S, Persson M, Jujic A et al.. “Measures of lung function and their relationship with advanced glycation end-products.” ERJ open research (2020). PMID: 32523964 ↗

    L2OTHERCited in: 2. Pathophysiology and Mechanism
  144. [144]

    Vanfleteren LEGW, Weidner J, Franssen FME et al.. “Biomarker-based clustering of patients with chronic obstructive pulmonary disease.” ERJ open research (2023). PMID: 36755966 ↗

    L4OTHERCited in: 2. Pathophysiology and Mechanism
  145. [145]

    Vogiatzis I, Marvisi M, Coolen J et al.. “Clinical highlights: messages from Munich.” ERJ open research (2015). PMID: 27730129 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  146. [146]

    Hayman YA, Sadofsky LR, Williamson JD et al.. “The effects of exogenous lipid on THP-1 cells: an in vitro model of airway aspiration?” ERJ open research (2017). PMID: 28344981 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  147. [147]

    Dvorkin-Gheva A, Vanderstocken G, Yildirim AÖ et al.. “Total particulate matter concentration skews cigarette smoke's gene expression profile.” ERJ open research (2016). PMID: 27995131 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  148. [148]

    Zhao P, Ding Y, Huang X et al.. “Endothelial injury biomarker EASIX predicts mortality risk in adults with chronic obstructive pulmonary disease: A retrospective cohort study.” Medicine (2026). PMID: 42432898 ↗

    L2COHORTCited in: 2. Pathophysiology and Mechanism
  149. [149]

    Long M, Qiu A, Jiang W et al.. “Time-series transcriptomic analysis of cigarette smoke-associated lung responses reveals COPD-related inflammatory and epithelial remodeling modules in murine models.” Frontiers in medicine (2026). PMID: 42422855 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  150. [150]

    Yang J, Liu Y, Meng Y et al.. “Qingre-Huatan-Liqi formula attenuates FPM-induced lung injury via modulation of MAPK signaling and NETs formation.” Frontiers in pharmacology (2026). PMID: 42422088 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  151. [151]

    Adhikari H, Sultana N, Goswami AM et al.. “The CHRNA5 rs16969968 variant is associated with MMP-9 expression and inflammatory signaling in COPD in a West Bengal population, India.” Frontiers in pharmacology (2026). PMID: 42422064 ↗

    L3OTHERCited in: 2. Pathophysiology and Mechanism
  152. [152]

    Wang MY, Chen TT, Kang JY et al.. “LDHA-mediated H3K14 lactylation promotes LRP5 transcription to damage airway epithelial barrier in chronic obstructive pulmonary disease.” Free radical biology & medicine (2026). PMID: 42413667 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  153. [153]

    Xu A, Lv Y, Li S et al.. “SPG7-Mediated Regulation of mPTP and Mitochondrial Flickering in COPD: A Bioinformatics-Based Prediction of Mechanistic Framework.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42404999 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism
  154. [154]

    Lin C, Huang S, Yang L et al.. “Macrophage spatiotemporal plasticity in pulmonary diseases: decoding the niche at single-cell resolution.” Frontiers in immunology (2026). PMID: 42396453 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism
  155. [155]

    Zanaboni P, Dinesen B, Hoaas H et al.. “Long-term Telerehabilitation or Unsupervised Training at Home for Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2023). PMID: 36480957 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  156. [156]

    Martinez FJ, Rabe KF, Ferguson GT et al.. “Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.” American journal of respiratory and critical care medicine (2021). PMID: 33252985 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  157. [157]

    Singh D, Martinez FJ, Hurst JR et al.. “Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).” American journal of respiratory and critical care medicine (2025). PMID: 39213002 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  158. [158]

    Bhatt SP, Rabe KF, Hanania NA et al.. “Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.” The Lancet. Respiratory medicine (2025). PMID: 39900091 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  159. [159]

    Ferguson GT, Rabe KF, Martinez FJ et al.. “Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.” The Lancet. Respiratory medicine (2018). PMID: 30232048 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  160. [160]

    Rabe KF, Celli BR, Wechsler ME et al.. “Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.” The Lancet. Respiratory medicine (2021). PMID: 34302758 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  161. [161]

    Saferali A, Qiao D, Kim W et al.. “C FTR variants are associated with chronic bronchitis in smokers.” The European respiratory journal (2022). PMID: 34996830 ↗

    L3SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
  162. [162]

    Bhatt SP, Rabe KF, Hanania NA et al.. “Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.” The New England journal of medicine (2024). PMID: 38767614 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  163. [163]

    Lipson DA, Barnhart F, Brealey N et al.. “Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.” The New England journal of medicine (2018). PMID: 29668352 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  164. [164]

    Yndigegn T, Lindahl B, Mars K et al.. “Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.” The New England journal of medicine (2024). PMID: 38587241 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  165. [165]

    Rabe KF, Martinez FJ, Ferguson GT et al.. “Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.” The New England journal of medicine (2020). PMID: 32579807 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  166. [166]

    Wedzicha JA, Banerji D, Chapman KR et al.. “Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.” The New England journal of medicine (2016). PMID: 27181606 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  167. [167]

    Aaron SD, Vandemheen KL, Whitmore GA et al.. “Early Diagnosis and Treatment of COPD and Asthma - A Randomized, Controlled Trial.” The New England journal of medicine (2024). PMID: 38767248 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
  168. [168]

    Zhou Y, Zhong NS, Li X et al.. “Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.” The New England journal of medicine (2017). PMID: 28877027 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  169. [169]

    Han MK, Ye W, Wang D et al.. “Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function.” The New England journal of medicine (2022). PMID: 36066078 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  170. [170]

    Lacasse Y, Sériès F, Corbeil F et al.. “Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease.” The New England journal of medicine (2020). PMID: 32937046 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  171. [171]

    Verstraete K, Gyselinck I, Huts H et al.. “Identifying azithromycin responders with an individual treatment effect model in COPD.” Thorax (2025). PMID: 40610208 ↗

    L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  172. [172]

    Chen W, Thomas J, Sadatsafavi M et al.. “Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.” The Lancet. Respiratory medicine (2015). PMID: 26208998 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  173. [173]

    Burns KEA, Stevenson J, Laird M et al.. “Non-invasive ventilation versus invasive weaning in critically ill adults: a systematic review and meta-analysis.” Thorax (2021). PMID: 34716282 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
  174. [174]

    Jenkins AR, Burtin C, Camp PG et al.. “Do pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis.” Thorax (2024). PMID: 38350731 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  175. [175]

    Barr RG, Bourbeau J, Camargo CA et al.. “Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.” Thorax (2006). PMID: 16844726 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  176. [176]

    Wang X, Chen L, Cai M et al.. “Air pollution associated with incidence and progression trajectory of chronic lung diseases: a population-based cohort study.” Thorax (2023). PMID: 36732083 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  177. [177]

    Simonds AK. “Home Mechanical Ventilation: An Overview.” Annals of the American Thoracic Society (2016). PMID: 27560387 ↗

    L5SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History
  178. [178]

    Morgan AD, Sharma C, Rothnie KJ et al.. “Chronic Obstructive Pulmonary Disease and the Risk of Stroke.” Annals of the American Thoracic Society (2017). PMID: 28459623 ↗

    L5SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
  179. [179]

    Wang L, Cai Y, Garssen J et al.. “The Bidirectional Gut-Lung Axis in Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2023). PMID: 36883945 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
  180. [180]

    Bhatt SP, Agusti A, Bafadhel M et al.. “Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2023). PMID: 37560988 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  181. [181]

    Chalmers JD, Aliberti S, Filonenko A et al.. “Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis.” American journal of respiratory and critical care medicine (2018). PMID: 29357265 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  182. [182]

    Divo M, Cote C, de Torres JP et al.. “Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease.” American journal of respiratory and critical care medicine (2012). PMID: 22561964 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
  183. [183]

    Parvizian MK, Dhaliwal M, Li J et al.. “Relationship between dietary patterns and COPD: a systematic review and meta-analysis.” ERJ open research (2020). PMID: 32420316 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors
  184. [184]

    Arif R, Pandey A, Zhao Y et al.. “Treatment of pulmonary hypertension associated with COPD: a systematic review.” ERJ open research (2022). PMID: 35198628 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History
  185. [185]

    Park SL, Lichtensztajn D, Yang J et al.. “Ambient Air Pollution and Chronic Obstructive Pulmonary Disease: The Multiethnic Cohort Study.” Annals of the American Thoracic Society (2025). PMID: 39847697 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 8. Long-term and Definitive Management, History and Evolution of Treatment
  186. [186]

    Wijnant SRA, De Roos E, Kavousi M et al.. “Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study.” The European respiratory journal (2020). PMID: 31601717 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  187. [187]

    Schols AM, Ferreira IM, Franssen FM et al.. “Nutritional assessment and therapy in COPD: a European Respiratory Society statement.” The European respiratory journal (2014). PMID: 25234804 ↗

    L1OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 11. Prognosis and Natural History
  188. [188]

    Han YY, Yan Q, Chen W et al.. “Child maltreatment, anxiety and depression, and asthma among British adults in the UK Biobank.” The European respiratory journal (2022). PMID: 35301250 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  189. [189]

    Doiron D, de Hoogh K, Probst-Hensch N et al.. “Air pollution, lung function and COPD: results from the population-based UK Biobank study.” The European respiratory journal (2019). PMID: 31285306 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  190. [190]

    Zhang PD, Zhang XR, Zhang A et al.. “Associations of genetic risk and smoking with incident COPD.” The European respiratory journal (2022). PMID: 34172472 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
  191. [191]

    Egerod L, Ter Haar EAMD, Karsdal MA et al.. “Comorbidity profiles in chronic obstructive pulmonary disease: a multicohort study.” ERJ open research (2025). PMID: 41158484 ↗

    L4COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  192. [192]

    Engel RM, de Luca K, Graham PL et al.. “Predictors of chronic obstructive pulmonary disease in women who have never smoked: a cohort study.” ERJ open research (2022). PMID: 35586447 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation
  193. [193]

    Olsson KM, Corte TJ, Kamp JC et al.. “Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management.” The Lancet. Respiratory medicine (2023). PMID: 37591300 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History
  194. [194]

    de Oca MM, Perez-Padilla R, Celli B et al.. “The global burden of COPD: epidemiology and effect of prevention strategies.” The Lancet. Respiratory medicine (2025). PMID: 40684784 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
  195. [195]

    Fabbri LM, Celli BR, Agustí A et al.. “COPD and multimorbidity: recognising and addressing a syndemic occurrence.” The Lancet. Respiratory medicine (2023). PMID: 37696283 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications
  196. [196]

    Menon AA, Putman RK, Sanders JL et al.. “Interstitial Lung Abnormalities, Emphysema, and Spirometry in Smokers.” Chest (2021). PMID: 34742688 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  197. [197]

    Citgez E, Zuur-Telgen M, van der Palen J et al.. “Stable-State Midrange Proadrenomedullin Is Associated With Severe Exacerbations in COPD.” Chest (2018). PMID: 29475034 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  198. [198]

    de-Torres JP, Marín JM, Casanova C et al.. “Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO.” Chest (2016). PMID: 26513409 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  199. [199]

    Forsslund H, Mikko M, Karimi R et al.. “Distribution of T-cell subsets in BAL fluid of patients with mild to moderate COPD depends on current smoking status and not airway obstruction.” Chest (2014). PMID: 24264182 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
  200. [200]

    Suissa S, Dell'Aniello S, Ernst P. “Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality.” Thorax (2012). PMID: 22684094 ↗

    L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  201. [201]

    Angelini ED, Yang J, Balte PP et al.. “Pulmonary emphysema subtypes defined by unsupervised machine learning on CT scans.” Thorax (2023). PMID: 37268414 ↗

    L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  202. [202]

    Zhang Y, Ye Z, Yang S et al.. “Proteomics-based risk prediction and drug targets identification for chronic obstructive pulmonary disease.” Thorax (2026). PMID: 40992936 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  203. [203]

    Pollock J, Polverino E, Dhar R et al.. “Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).” Thorax (2025). PMID: 40122611 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History
  204. [204]

    Yang LF, Yang Z. “Associations of the systemic immune-inflammation index and systemic inflammatory response index with chronic obstructive pulmonary disease: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42434011 ↗

    L3SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
  205. [205]

    Qin C, Lin S, Pang L et al.. “Risk factors for sepsis: a systematic review and meta-analysis.” Frontiers in public health (2026). PMID: 42433399 ↗

    L3SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
  206. [206]

    Xu J, Zhang P, Wang Y et al.. “Association between extreme temperature exposure and COPD health outcomes in China: study protocol for a systematic review.” Frontiers in medicine (2026). PMID: 42428276 ↗

    L5SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  207. [207]

    Wang Y, Ding C, Liu Y et al.. “Bidirectional association between COPD and AF: a systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42403902 ↗

    L3SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  208. [208]

    Wang Y, Liang Q, Li X et al.. “Adherence to pulmonary rehabilitation in COPD: determinants and development of a parsimonious risk model. A systematic review.” European journal of physical and rehabilitation medicine (2026). PMID: 42394545 ↗

    L3SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  209. [209]

    Schrijver J, Lenferink A, Brusse-Keizer M et al.. “Self-management interventions for people with chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2022). PMID: 35001366 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  210. [210]

    Raveling T, Vonk J, Struik FM et al.. “Chronic non-invasive ventilation for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2021). PMID: 34368950 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History
  211. [211]

    Puhan MA, Gimeno-Santos E, Cates CJ et al.. “Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2016). PMID: 27930803 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  212. [212]

    Edgar K, Iliffe S, Doll HA et al.. “Admission avoidance hospital at home.” The Cochrane database of systematic reviews (2024). PMID: 38438116 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  213. [213]

    Osadnik CR, Tee VS, Carson-Chahhoud KV et al.. “Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2017). PMID: 28702957 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History
  214. [214]

    Ni H, Aye SZ, Naing C. “Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2022). PMID: 35616126 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
  215. [215]

    Poole P, Sathananthan K, Fortescue R. “Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2019). PMID: 31107966 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 11. Prognosis and Natural History
  216. [216]

    Poot CC, Meijer E, Kruis AL et al.. “Integrated disease management interventions for patients with chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2021). PMID: 34495549 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  217. [217]

    Janjua S, Mathioudakis AG, Fortescue R et al.. “Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.” The Cochrane database of systematic reviews (2021). PMID: 33448349 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  218. [218]

    Janjua S, Carter D, Threapleton CJ et al.. “Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2021). PMID: 34693988 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  219. [219]

    Rasmussen DB, Meteran H, Lamberts M et al.. “Beta-blockers and mortality after myocardial infarction in patients with and without chronic obstructive pulmonary disease - A Danish nationwide cohort study of 96,567 patients.” Respiratory medicine (2026). PMID: 42431469 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  220. [220]

    Zhang Z, Sun X, Ren J et al.. “Independent and interactive effects of personal light exposure and air pollution on incident COPD: A prospective cohort study with 13 million hours of light sensor data.” Environmental pollution (Barking, Essex : 1987) (2026). PMID: 42413849 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors
  221. [221]

    Drick N, Valtin C, Fuge J. “Effectiveness of treatment with tezepelumab in patients with severe asthma, smoking asthmatics and patients with severe Asthma and COPD: A real-world cohort study.” The journal of allergy and clinical immunology. In practice (2026). PMID: 42386154 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  222. [222]

    Calverley PMA, Walker PP. “Contemporary Concise Review 2022: Chronic obstructive pulmonary disease.” Respirology (Carlton, Vic.) (2023). PMID: 36922031 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  223. [223]

    Ko FW, Chan KP, Hui DS et al.. “Acute exacerbation of COPD.” Respirology (Carlton, Vic.) (2016). PMID: 27028990 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  224. [224]

    Negewo NA, Gibson PG, McDonald VM. “COPD and its comorbidities: Impact, measurement and mechanisms.” Respirology (Carlton, Vic.) (2015). PMID: 26374280 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 11. Prognosis and Natural History
  225. [225]

    López-Campos JL, Tan W, Soriano JB. “Global burden of COPD.” Respirology (Carlton, Vic.) (2015). PMID: 26494423 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  226. [226]

    Lan CC, Su WL, Yang MC et al.. “Predictive role of neutrophil-percentage-to-albumin, neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios for mortality in patients with COPD: Evidence from NHANES 2011-2018.” Respirology (Carlton, Vic.) (2023). PMID: 37655985 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  227. [227]

    Nambiar S, Bong How S, Gummer J et al.. “Metabolomics in chronic lung diseases.” Respirology (Carlton, Vic.) (2019). PMID: 30907495 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors
  228. [228]

    Suen AO, Iyer AS, Cenzer I et al.. “National Prevalence of Social Isolation and Loneliness in Adults with Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2023). PMID: 37463307 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue
  229. [229]

    Yen FS, Wei JC, Huang YH et al.. “SGLT-2 Inhibitors and the Risk of Chronic Obstructive Pulmonary Disease Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease Patients.” Annals of the American Thoracic Society (2025). PMID: 39938066 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  230. [230]

    George MP, Masur H, Norris KA et al.. “Infections in the immunosuppressed host.” Annals of the American Thoracic Society (2014). PMID: 25148427 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History
  231. [231]

    Khor YH, Renzoni EA, Visca D et al.. “Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns.” ERJ open research (2019). PMID: 31544111 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  232. [232]

    Butler SJ, Li LSK, Ellerton L et al.. “Prevalence of comorbidities and impact on pulmonary rehabilitation outcomes.” ERJ open research (2019). PMID: 31832430 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  233. [233]

    Agustí A, Celli B. “Natural history of COPD: gaps and opportunities.” ERJ open research (2017). PMID: 29255718 ↗

    L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
  234. [234]

    Nici L, Mammen MJ, Charbek E et al.. “Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2020). PMID: 32283960 ↗

    L1GUIDELINECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management
  235. [235]

    Anzueto A, Barjaktarevic IZ, Siler TM et al.. “Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).” American journal of respiratory and critical care medicine (2023). PMID: 37364283 ↗

    L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  236. [236]

    Criner GJ, Sue R, Wright S et al.. “A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE).” American journal of respiratory and critical care medicine (2018). PMID: 29787288 ↗

    L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History
  237. [237]

    Griffith DE, Eagle G, Thomson R et al.. “Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.” American journal of respiratory and critical care medicine (2018). PMID: 30216086 ↗

    L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue
  238. [238]

    Ramakrishnan S, Russell REK, Mahmood HR et al.. “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.” The Lancet. Respiratory medicine (2024). PMID: 39615502 ↗

    L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  239. [239]

    Jenkins CR, Martin A, Chang CL et al.. “Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial.” The Lancet. Respiratory medicine (2026). PMID: 41579873 ↗

    L1RCTCited in: 4. Clinical Presentation
  240. [240]

    Tse HN, Raiteri L, Wong KY et al.. “High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.” Chest (2013). PMID: 23348146 ↗

    L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  241. [241]

    He LX, Yang L, Xiao ZK et al.. “Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II): A Phase 2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial.” Chest (2026). PMID: 41812987 ↗

    L1RCTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  242. [242]

    Celli B, Crater G, Kilbride S et al.. “Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.” Chest (2014). PMID: 24385182 ↗

    L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  243. [243]

    Yang M, Li Y, Jiang Y et al.. “Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.” The European respiratory journal (2023). PMID: 36137586 ↗

    L1SR_OBSCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  244. [244]

    Bhatt SP, Rabe KF, Hanania NA et al.. “Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.” The New England journal of medicine (2023). PMID: 37272521 ↗

    L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  245. [245]

    Vogelmeier C, Hederer B, Glaab T et al.. “Tiotropium versus salmeterol for the prevention of exacerbations of COPD.” The New England journal of medicine (2011). PMID: 21428765 ↗

    L1RCTCited in: 4. Clinical Presentation
  246. [246]

    Magnussen H, Disse B, Rodriguez-Roisin R et al.. “Withdrawal of inhaled glucocorticoids and exacerbations of COPD.” The New England journal of medicine (2014). PMID: 25196117 ↗

    L1RCTCited in: 4. Clinical Presentation
  247. [247]

    Sciurba FC, Ernst A, Herth FJ et al.. “A randomized study of endobronchial valves for advanced emphysema.” The New England journal of medicine (2010). PMID: 20860505 ↗

    L1RCTCited in: 4. Clinical Presentation, 10. Complications
  248. [248]

    Peters SP, Kunselman SJ, Icitovic N et al.. “Tiotropium bromide step-up therapy for adults with uncontrolled asthma.” The New England journal of medicine (2010). PMID: 20979471 ↗

    L1RCTCited in: 4. Clinical Presentation
  249. [249]

    Machado A, Dias C, Paixão C et al.. “Short-term effects of home-based pulmonary rehabilitation during outpatient-managed exacerbations of COPD: a randomised controlled trial.” Thorax (2025). PMID: 39689939 ↗

    L1RCTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  250. [250]

    Puzzolo E, Fleeman N, Lorenzetti F et al.. “Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses.” The Lancet. Respiratory medicine (2024). PMID: 38310914 ↗

    L2SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  251. [251]

    Xu JF, Zheng HZ, Lu HW et al.. “Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study.” The Lancet. Respiratory medicine (2025). PMID: 39805296 ↗

    L2COHORTCited in: 4. Clinical Presentation, History and Evolution of Treatment
  252. [252]

    Kawachi S, Hoffman M, Holland AE. “Clinical Features Associated With Fatigue in People With Fibrotic Interstitial Lung Disease: Cross-Sectional Study.” Respirology (Carlton, Vic.) (2025). PMID: 40685600 ↗

    L4RCTCited in: 4. Clinical Presentation
  253. [253]

    Heslop-Marshall K, Baker C, Carrick-Sen D et al.. “Randomised controlled trial of cognitive behavioural therapy in COPD.” ERJ open research (2018). PMID: 30479999 ↗

    L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue
  254. [254]

    Zhang J, Perret JL, Chang AB et al.. “Risk factors for chronic cough in adults: A systematic review and meta-analysis.” Respirology (Carlton, Vic.) (2021). PMID: 34658107 ↗

    L2SR_OBSCited in: 4. Clinical Presentation
  255. [255]

    Vestbo J, Hurd SS, Agustí AG et al.. “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.” American journal of respiratory and critical care medicine (2012). PMID: 22878278 ↗

    L1REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment
  256. [256]

    Singh D, Agusti A, Anzueto A et al.. “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.” The European respiratory journal (2019). PMID: 30846476 ↗

    L1REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, History and Evolution of Treatment
  257. [257]

    Derom E, van Weel C, Liistro G et al.. “Primary care spirometry.” The European respiratory journal (2008). PMID: 18166597 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 13. Prevention, Screening & Surveillance
  258. [258]

    Zielinski J, Bednarek M, Górecka D et al.. “Increasing COPD awareness.” The European respiratory journal (2006). PMID: 16585092 ↗

    L4OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 13. Prevention, Screening & Surveillance
  259. [259]

    Mannino DM, Watt G, Hole D et al.. “The natural history of chronic obstructive pulmonary disease.” The European respiratory journal (2006). PMID: 16507865 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
  260. [260]

    Cho PSP, Fletcher HV, Patel IS et al.. “Cough hypersensitivity and suppression in COPD.” The European respiratory journal (2021). PMID: 33303553 ↗

    L3OTHERCited in: 4. Clinical Presentation
  261. [261]

    Bulpa P, Dive A, Sibille Y. “Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.” The European respiratory journal (2007). PMID: 17906086 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  262. [262]

    Pradere P, Gauvain C, Danel C et al.. “Airway-Centered Fibroelastosis: A Distinct Entity.” Chest (2016). PMID: 26836939 ↗

    L4OTHERCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  263. [263]

    Smallwood N, Pascoe A, Goh N et al.. “The SINFONIA Study: A Randomised Controlled Trial to Determine Feasibility and Effectiveness of Online Group Singing for People With COPD or ILD and Breathlessness.” Respirology (Carlton, Vic.) (2026). PMID: 42413924 ↗

    L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  264. [264]

    Philip J, Chang YK, Collins A et al.. “Consensus palliative care referral criteria for people with chronic obstructive pulmonary disease.” Thorax (2024). PMID: 39174326 ↗

    L5OTHERCited in: 4. Clinical Presentation
  265. [265]

    Duvoix A, Dickens J, Haq I et al.. “Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease.” Thorax (2012). PMID: 22744884 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
  266. [266]

    Lunardi AC, Marques DA Silva CC, Censo CM et al.. “The addition of motivational interventions to pulmonary rehabilitation does not improve physical and psychosocial outcomes in patients with chronic obstructive pulmonary disease: a systematic review with metanalyses.” European journal of physical and rehabilitation medicine (2026). PMID: 42394544 ↗

    L1SR_OBSCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  267. [267]

    Ammous O, Feki W, Lotfi T et al.. “Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2023). PMID: 36606682 ↗

    L1SR_OBSCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  268. [268]

    van Geffen WH, Tan DJ, Walters JA et al.. “Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2023). PMID: 38054551 ↗

    L1SR_OBSCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, History and Evolution of Treatment
  269. [269]

    Kelly C, Grundy S, Lynes D et al.. “Self-management for bronchiectasis.” The Cochrane database of systematic reviews (2018). PMID: 29411860 ↗

    L1SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  270. [270]

    Cochrane B, Akhunji MZ, Xuan W et al.. “Breathlessness Matters - Australian Cohort Study Evaluating the Impact of a Multidisciplinary, Home-Based Breathlessness Intervention Service Targeting Patients with Chronic Obstructive Pulmonary Disease (COPD).” International journal of chronic obstructive pulmonary disease (2026). PMID: 42367347 ↗

    L2COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  271. [271]

    Ye X, Le S, Han S et al.. “Risk Factors and Prediction of Chronic Obstructive Pulmonary Disease After Pulmonary Tuberculosis: A Prospective Cohort Study.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42328419 ↗

    L2COHORTCited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 10. Complications, 13. Prevention, Screening & Surveillance
  272. [272]

    Singh D. “Pharmacological treatment of stable chronic obstructive pulmonary disease.” Respirology (Carlton, Vic.) (2021). PMID: 33829619 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  273. [273]

    Armstrong M, Vogiatzis I. “Personalized exercise training in chronic lung diseases.” Respirology (Carlton, Vic.) (2019). PMID: 31270909 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
  274. [274]

    Ko FW, Hui DS. “Air pollution and chronic obstructive pulmonary disease.” Respirology (Carlton, Vic.) (2012). PMID: 22142380 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue
  275. [275]

    Owens RL, Macrea MM, Teodorescu M. “The overlaps of asthma or COPD with OSA: A focused review.” Respirology (Carlton, Vic.) (2017). PMID: 28677827 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
  276. [276]

    Neder JA, Berton DC, Müller PT et al.. “Ventilatory Inefficiency and Exertional Dyspnea in Early Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2017). PMID: 28345959 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
  277. [277]

    Tighe RM, Torres LR, Miller R. “Evaluating Deployment-related Respiratory Diseases in Military Veterans.” Annals of the American Thoracic Society (2025). PMID: 40632889 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, History and Evolution of Treatment
  278. [278]

    Mahler DA, Halpin DMG. “Personalizing Selection of Inhaled Delivery Systems in Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2023). PMID: 37499210 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management
  279. [279]

    Bodduluri S, Reinhardt JM, Hoffman EA et al.. “Recent Advances in Computed Tomography Imaging in Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2018). PMID: 28812906 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  280. [280]

    Wang Q, Ma Q. “Number Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-Analysis.” COPD (2026). PMID: 42405817 ↗

    L1SR_OBSCited in: 4. Clinical Presentation
  281. [281]

    Shati A, Abdulmutaali A, Alsaeed N. “Respiratory Disease Detection: A Systematic Review of AI-Based Approaches, from Audio and Visual Unimodal Methods to Multimodal Integration.” Diagnostics (Basel, Switzerland) (2026). PMID: 42351549 ↗

    L5SR_OBSCited in: 4. Clinical Presentation
  282. [282]

    Roche N, Devillier P, Berger P et al.. “Individual trajectory-based care for COPD: getting closer, but not there yet.” ERJ open research (2021). PMID: 34912881 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management
  283. [283]

    Epiu I, Gandevia SC, Boswell-Ruys CL et al.. “Tongue strength and swallowing dynamics in chronic obstructive pulmonary disease.” ERJ open research (2021). PMID: 34262969 ↗

    L3OTHERCited in: 4. Clinical Presentation
  284. [284]

    Stone PW, Hickman K, Steiner MC et al.. “Predictors of pulmonary rehabilitation completion in the UK.” ERJ open research (2021). PMID: 33585658 ↗

    L3OTHERCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  285. [285]

    Zhou Y, Ampon MR, Abramson MJ et al.. “Clinical characteristics of adults with self-reported diagnosed asthma and/or COPD: data from the BOLD Australia Study.” ERJ open research (2023). PMID: 37609600 ↗

    L2OTHERCited in: 4. Clinical Presentation
  286. [286]

    Lirong L, Kangying W. “Evaluation of squamous cell carcinoma antigen as a diagnostic biomarker in pulmonary diseases: a male cohort study.” Diagnostic pathology (2026). PMID: 42374516 ↗

    L3COHORTCited in: 4. Clinical Presentation
  287. [287]

    Gong Z, Wang J, Chen M et al.. “Clinical characteristics, symptom burden, and pulmonary function trajectories of spirometry- and MMEF-defined bronchodilator responsiveness in COPD: a single-center prospective study.” Journal of thoracic disease (2026). PMID: 42306736 ↗

    L2COHORTCited in: 4. Clinical Presentation
  288. [288]

    Huanzhang D, Hui W, Qinjun Y et al.. “A multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable chronic obstructive pulmonary disease.” Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2026). PMID: 42365412 ↗

    L1RCTCited in: 4. Clinical Presentation
  289. [289]

    Nagata K, Horie T, Chohnabayashi N et al.. “Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2022). PMID: 35771533 ↗

    L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  290. [290]

    Tana A, Valipour A, Ing A et al.. “Airway Scaffolds for Emphysema-related Hyperinflation: Six-Month Results from the BREATHE Trial.” American journal of respiratory and critical care medicine (2025). PMID: 40387356 ↗

    L4TRIAL_NONRANDOMCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  291. [291]

    Ramakrishnan S, Jeffers H, Langford-Wiley B et al.. “Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.” The Lancet. Respiratory medicine (2023). PMID: 37924830 ↗

    L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  292. [292]

    Terzikhan N, Sun F, Verhamme FM et al.. “Heritability and genome-wide association study of diffusing capacity of the lung.” The European respiratory journal (2018). PMID: 30049742 ↗

    L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  293. [293]

    Butler CC, Gillespie D, White P et al.. “C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations.” The New England journal of medicine (2019). PMID: 31291514 ↗

    L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
  294. [294]

    Gioia F, Walti LN, Orchanian-Cheff A et al.. “Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis.” The Lancet. Respiratory medicine (2024). PMID: 38185135 ↗

    L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
  295. [295]

    Suryadevara R, Gregory A, Lu R et al.. “Blood-based Transcriptomic and Proteomic Biomarkers of Emphysema.” American journal of respiratory and critical care medicine (2024). PMID: 37917913 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
  296. [296]

    Celli BR, Fabbri LM, Aaron SD et al.. “Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice.” American journal of respiratory and critical care medicine (2023). PMID: 36701677 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
  297. [297]

    Martinez FJ, Agusti A, Celli BR et al.. “Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward.” American journal of respiratory and critical care medicine (2022). PMID: 34672872 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  298. [298]

    Halpin DMG, Criner GJ, Papi A et al.. “Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2021). PMID: 33146552 ↗

    L1REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications, 13. Prevention, Screening & Surveillance
  299. [299]

    Ritchie AI, Donaldson GC, Hoffman EA et al.. “Structural Predictors of Lung Function Decline in Young Smokers with Normal Spirometry.” American journal of respiratory and critical care medicine (2024). PMID: 38175920 ↗

    L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  300. [300]

    Ambrosino N, Guarracino F. “Unusual applications of noninvasive ventilation.” The European respiratory journal (2011). PMID: 21349915 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 12. Special Populations & Pregnancy
  301. [301]

    Leduc C, Antoni D, Charloux A et al.. “Comorbidities in the management of patients with lung cancer.” The European respiratory journal (2017). PMID: 28356370 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
  302. [302]

    Higbee DH, Granell R, Davey Smith G et al.. “Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis.” The Lancet. Respiratory medicine (2021). PMID: 34739861 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  303. [303]

    Radicioni G, Ceppe A, Ford AA et al.. “Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.” The Lancet. Respiratory medicine (2021). PMID: 34058148 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  304. [304]

    Vanfleteren LEGW, Spruit MA, Wouters EFM et al.. “Management of chronic obstructive pulmonary disease beyond the lungs.” The Lancet. Respiratory medicine (2016). PMID: 27264777 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  305. [305]

    Niu Y, Niu H, Meng X et al.. “Associations Between Air Pollution and the Onset of Acute Exacerbations of COPD: A Time-Stratified Case-Crossover Study in China.” Chest (2024). PMID: 38906462 ↗

    L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue
  306. [306]

    Faisal A, Zoumot Z, Shah PL et al.. “Effective Bronchoscopic Lung Volume Reduction Accelerates Exercise Oxygen Uptake Kinetics in Emphysema.” Chest (2016). PMID: 26111199 ↗

    L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  307. [307]

    Rush B, Hertz P, Bond A et al.. “Use of Palliative Care in Patients With End-Stage COPD and Receiving Home Oxygen: National Trends and Barriers to Care in the United States.” Chest (2016). PMID: 27387892 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
  308. [308]

    Kesimer M, Ford AA, Ceppe A et al.. “Airway Mucin Concentration as a Marker of Chronic Bronchitis.” The New England journal of medicine (2017). PMID: 28877023 ↗

    L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  309. [309]

    Barr RG, Bluemke DA, Ahmed FS et al.. “Percent emphysema, airflow obstruction, and impaired left ventricular filling.” The New England journal of medicine (2010). PMID: 20089972 ↗

    L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
  310. [310]

    Cosío BG, Pascual-Guardia S, Borras-Santos A et al.. “Phenotypic characterisation of early COPD: a prospective case-control study.” ERJ open research (2020). PMID: 33043045 ↗

    L3CASE_CONTROLCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  311. [311]

    Bradley C, Boland A, Clarke L et al.. “Diagnosis and treatment outcomes from prebronchodilator spirometry performed alongside lung cancer screening in a Lung Health Check programme.” Thorax (2023). PMID: 36972979 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  312. [312]

    McClean KM, Kee F, Young IS et al.. “Obesity and the lung: 1. Epidemiology.” Thorax (2008). PMID: 18587034 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  313. [313]

    Mathioudakis AG, Janssens W, Sivapalan P et al.. “Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits.” Thorax (2020). PMID: 32217784 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  314. [314]

    De Matteis S, Jarvis D, Darnton L et al.. “Lifetime occupational exposures and chronic obstructive pulmonary disease risk in the UK Biobank cohort.” Thorax (2022). PMID: 35082144 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  315. [315]

    Shen H, Zheng R, Du M et al.. “Environmental pollutants exposure-derived extracellular vesicles: crucial players in respiratory disorders.” Thorax (2024). PMID: 38631896 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
  316. [316]

    Herron M, Roche S, Fraughen DD et al.. “Optimising bronchoalveolar lavage: lessons from alpha-1 antitrypsin deficiency.” Thorax (2024). PMID: 39586664 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  317. [317]

    Williamson A, Martineau AR, Jolliffe D et al.. “Vitamin D for the management of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2024). PMID: 39329240 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
  318. [318]

    Ngai SP, Jones AY, Tam WW. “Tai Chi for chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2016). PMID: 27272131 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
  319. [319]

    Griesel M, Wagner C, Mikolajewska A et al.. “Inhaled corticosteroids for the treatment of COVID-19.” The Cochrane database of systematic reviews (2022). PMID: 35262185 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 13. Prevention, Screening & Surveillance
  320. [320]

    Ferreira IM, Brooks D, White J et al.. “Nutritional supplementation for stable chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2012). PMID: 23235577 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  321. [321]

    Irons JY, Kenny DT, Chang AB. “Singing for children and adults with bronchiectasis.” The Cochrane database of systematic reviews (2010). PMID: 20166097 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  322. [322]

    Jones AP, Rowe BH. “WITHDRAWN: Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis.” The Cochrane database of systematic reviews (2011). PMID: 21735379 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
  323. [323]

    van Agteren JE, Carson KV, Tiong LU et al.. “Lung volume reduction surgery for diffuse emphysema.” The Cochrane database of systematic reviews (2016). PMID: 27739074 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  324. [324]

    Cross AJ, Thomas D, Liang J et al.. “Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care.” The Cochrane database of systematic reviews (2022). PMID: 35514131 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  325. [325]

    Chan KH, Liu WC, Chang YC et al.. “Association Between Chronic Obstructive Pulmonary Disease and Survival in Patients with Lung Cancer: A Nationwide Cohort Study.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42371564 ↗

    L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
  326. [326]

    Mineshita M, Slebos DJ. “Bronchoscopic interventions for chronic obstructive pulmonary disease.” Respirology (Carlton, Vic.) (2014). PMID: 25124070 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  327. [327]

    Agustí A, Rapsomaniki E, Beasley R et al.. “Treatable traits in the NOVELTY study.” Respirology (Carlton, Vic.) (2022). PMID: 35861464 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
  328. [328]

    Fujino N, Sugiura H. “Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine.” Respirology (Carlton, Vic.) (2026). PMID: 41881492 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
  329. [329]

    Turino GM, Ma S, Cantor JO et al.. “Biomarkers in Alpha-1 Antitrypsin Deficiency Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2016). PMID: 27564670 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  330. [330]

    Robichaux CE, Baldomero AK, Gravely AA et al.. “Fine Particulate Matter and Mortality in Chronic Obstructive Pulmonary Disease with Multimorbidity.” Annals of the American Thoracic Society (2025). PMID: 40315387 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management
  331. [331]

    Balasubramanian A, Putcha N, MacIntyre NR et al.. “Diffusing Capacity and Mortality in Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2023). PMID: 35969416 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  332. [332]

    O'Donnell DE, Ciavaglia CE, Neder JA. “When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences.” Annals of the American Thoracic Society (2014). PMID: 24625243 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  333. [333]

    Lee J, Sun J, Lee HW. “Chronic Obstructive Pulmonary Disease and Inhaled Treatment Effects on Mortality in Patients with Lung Cancer.” Annals of the American Thoracic Society (2025). PMID: 40569182 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
  334. [334]

    Buhr RG, Jackson NJ, Fazio JC et al.. “Characteristics Associated with Lung Function Trajectories: An Analysis of the SPIROMICS Cohort.” Annals of the American Thoracic Society (2025). PMID: 40198759 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  335. [335]

    Bhatt SP, Nakhmani A, Thimmegowda NM et al.. “Parameter D: New Measure of Airflow Obstruction.” Annals of the American Thoracic Society (2023). PMID: 36989246 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  336. [336]

    Ajayababu A, Antony A, Goyal B et al.. “Prevalence of allergic bronchopulmonary aspergillosis/Aspergillus sensitization in chronic obstructive pulmonary disease: A systematic review and meta-analysis.” Respiratory investigation (2026). PMID: 42361722 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  337. [337]

    Smith E, Thomas M, Calik-Kutukcu E et al.. “ERS International Congress 2020 Virtual: highlights from the Allied Respiratory Professionals Assembly.” ERJ open research (2021). PMID: 33585651 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  338. [338]

    Karlsson N, Atkinson MJ, Müllerová H et al.. “Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD.” ERJ open research (2021). PMID: 33569501 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  339. [339]

    Ostadan F, Donovan AA, Matouk E et al.. “Computed tomography reveals hypertrophic remodelling of the diaphragm in cystic fibrosis but not in COPD.” ERJ open research (2023). PMID: 37753287 ↗

    L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  340. [340]

    Vestbo J, Janson C, Nuevo J et al.. “Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design.” ERJ open research (2020). PMID: 33083435 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  341. [341]

    Balasubramanian A, Henderson RJ, Putcha N et al.. “Haemoglobin as a biomarker for clinical outcomes in chronic obstructive pulmonary disease.” ERJ open research (2021). PMID: 34322549 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  342. [342]

    Liang X, Zheng J, Gao Y et al.. “Clinical application of oscillometry in respiratory diseases: an impulse oscillometry registry.” ERJ open research (2022). PMID: 36267898 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
  343. [343]

    Ratanawatkul P, Oh A, Richards JC et al.. “Performance of pulmonary artery dimensions measured on high-resolution computed tomography scan for identifying pulmonary hypertension.” ERJ open research (2020). PMID: 32055634 ↗

    L3OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
  344. [344]

    . “[Chinese practice guideline for the diagnosis and treatment of chronic obstructive pulmonary disease (2026 revision): protocol].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2026). PMID: 42373445 ↗

    L5GUIDELINECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue
  345. [345]

    Vázquez PF, Díez-Manglano J. “High Prevalence of Non-thyroidal Illness Syndrome in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis.” The Eurasian journal of medicine (2026). PMID: 42364217 ↗

    L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  346. [346]

    Guo C, Du Y, Xiao Q et al.. “[Effect of external diaphragmatic pacing on diaphragmatic function and weaning success rate in patients with acute exacerbations of chronic obstructive pulmonary disease undergoing invasive mechanical ventilation].” Zhonghua wei zhong bing ji jiu yi xue (2026). PMID: 42427323 ↗

    L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification
  347. [347]

    Gurabi Z, Zenner M, van den Dool W et al.. “Outcomes and risk factors for mortality in patients with pulmonary non-tuberculous mycobacterial infections: A single-center retrospective cohort study.” Pneumologie (Stuttgart, Germany) (2026). PMID: 42413514 ↗

    L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  348. [348]

    Jiang Y, Li Y, Du Y et al.. “Impact of chronic obstructive pulmonary disease on the prognosis of patients with extensive-stage small-cell lung cancer treated with chemoimmunotherapy.” Translational lung cancer research (2026). PMID: 42433226 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  349. [349]

    Dai L, Shen K, Su Q et al.. “Prevalence and risk factors of small airway dysfunction among rural residents in Western China: a real-world cross-sectional study.” NPJ primary care respiratory medicine (2026). PMID: 42431951 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  350. [350]

    Yazıcı MM, Ataş İ, Yılmaz GN et al.. “Evaluating the Roth and Dyspnea severity score for emergency department discharge in exacerbations of chronic obstructive pulmonary disease.” The American journal of emergency medicine (2026). PMID: 42430863 ↗

    L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
  351. [351]

    Lipson DA, Barnacle H, Birk R et al.. “FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2017). PMID: 28375647 ↗

    L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  352. [352]

    Kaasgaard M, Rasmussen DB, Andreasson KH et al.. “Use of Singing for Lung Health as an alternative training modality within pulmonary rehabilitation for COPD: a randomised controlled trial.” The European respiratory journal (2022). PMID: 34625480 ↗

    L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  353. [353]

    Köhnlein T, Windisch W, Köhler D et al.. “Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial.” The Lancet. Respiratory medicine (2014). PMID: 25066329 ↗

    L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  354. [354]

    Gosselink R, De Vos J, van den Heuvel SP et al.. “Impact of inspiratory muscle training in patients with COPD: what is the evidence?” The European respiratory journal (2011). PMID: 21282809 ↗

    L1SR_OBSCited in: 6. Severity, Staging and Risk Stratification
  355. [355]

    Calverley PM, Anderson JA, Celli B et al.. “Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.” The New England journal of medicine (2007). PMID: 17314337 ↗

    L1RCTCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  356. [356]

    Criner GJ, Connett JE, Aaron SD et al.. “Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.” The New England journal of medicine (2014). PMID: 24836125 ↗

    L1RCTCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  357. [357]

    Tashkin DP, Celli B, Senn S et al.. “A 4-year trial of tiotropium in chronic obstructive pulmonary disease.” The New England journal of medicine (2008). PMID: 18836213 ↗

    L1RCTCited in: 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
  358. [358]

    Njoku CM, Hurst JR, Kinsman L et al.. “COPD in Africa: risk factors, hospitalisation, readmission and associated outcomes-a systematic review and meta-analysis.” Thorax (2023). PMID: 36635039 ↗

    L2SR_OBSCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue
  359. [359]

    Camillo CA, Osadnik CR, van Remoortel H et al.. “Effect of "add-on" interventions on exercise training in individuals with COPD: a systematic review.” ERJ open research (2016). PMID: 27730178 ↗

    L1SR_OBSCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue
  360. [360]

    Hamzaoui O, Monnet X, Teboul JL. “Pulsus paradoxus.” The European respiratory journal (2012). PMID: 23222878 ↗

    L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue
  361. [361]

    Cutting CC, Rose JA, Tukpah AC et al.. “Interstitial lung abnormalities, coronary heart disease and mortality.” The European respiratory journal (2025). PMID: 40610050 ↗

    L2OTHERCited in: 6. Severity, Staging and Risk Stratification
  362. [362]

    . “Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.” The Lancet. Respiratory medicine (2020). PMID: 32526187 ↗

    L2OTHERCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  363. [363]

    Fang L, Gao P, Bao H et al.. “Chronic obstructive pulmonary disease in China: a nationwide prevalence study.” The Lancet. Respiratory medicine (2018). PMID: 29650407 ↗

    L4OTHERCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  364. [364]

    Quanjer PH, Ruppel GL, Langhammer A et al.. “Bronchodilator Response in FVC Is Larger and More Relevant Than in FEV1 in Severe Airflow Obstruction.” Chest (2016). PMID: 28040521 ↗

    L4OTHERCited in: 6. Severity, Staging and Risk Stratification
  365. [365]

    McCarthy B, Casey D, Devane D et al.. “Pulmonary rehabilitation for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2015). PMID: 25705944 ↗

    L1SR_OBSCited in: 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  366. [366]

    Cox NS, Dal Corso S, Hansen H et al.. “Telerehabilitation for chronic respiratory disease.” The Cochrane database of systematic reviews (2021). PMID: 33511633 ↗

    L1SR_OBSCited in: 6. Severity, Staging and Risk Stratification, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  367. [367]

    Mammen MJ, Sethi S. “COPD and the microbiome.” Respirology (Carlton, Vic.) (2016). PMID: 26852737 ↗

    L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue
  368. [368]

    Kimura Y, Jo T, Inoue N et al.. “Gabapentinoids and Risk for Exacerbation of Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2025). PMID: 40668951 ↗

    L2OTHERCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  369. [369]

    Wouters EFM. “Obesity and Metabolic Abnormalities in Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2017). PMID: 29161076 ↗

    L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  370. [370]

    Holguin F. “Oxidative stress in airway diseases.” Annals of the American Thoracic Society (2013). PMID: 24313766 ↗

    L5REVIEW_NARRATIVECited in: 6. Severity, Staging and Risk Stratification
  371. [371]

    Bertoche MP, Furlanetto KC, Hirata RP et al.. “Assessment of sedentary behaviour in individuals with COPD: how many days are necessary?” ERJ open research (2023). PMID: 37650084 ↗

    L4OTHERCited in: 6. Severity, Staging and Risk Stratification
  372. [372]

    Man WD, Puhan MA, Harrison SL et al.. “Pulmonary rehabilitation and severe exacerbations of COPD: solution or white elephant?” ERJ open research (2015). PMID: 27730157 ↗

    L5OTHERCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  373. [373]

    Kim HJ, Park HS, Jung J et al.. “Prevalence, causes, management strategies, and outcomes of secondary interventions during long-term follow-up after endovascular aneurysm repair: a retrospective cohort study.” Annals of surgical treatment and research (2026). PMID: 42428330 ↗

    L2COHORTCited in: 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management
  374. [374]

    Jacobs SS, Krishnan JA, Lederer DJ et al.. “Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2020). PMID: 33185464 ↗

    L1GUIDELINECited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
  375. [375]

    Rochwerg B, Brochard L, Elliott MW et al.. “Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure.” The European respiratory journal (2017). PMID: 28860265 ↗

    L1GUIDELINECited in: 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
  376. [376]

    Lipson DA, Crim C, Criner GJ et al.. “Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2020). PMID: 32162970 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue
  377. [377]

    Beaumont M, Mialon P, Le Ber C et al.. “Effects of inspiratory muscle training on dyspnoea in severe COPD patients during pulmonary rehabilitation: controlled randomised trial.” The European respiratory journal (2018). PMID: 29371379 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  378. [378]

    Singh D, Brightling CE, Rabe KF et al.. “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.” The Lancet. Respiratory medicine (2024). PMID: 39653044 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  379. [379]

    Christenson SA, Hanania NA, Bhatt SP et al.. “Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.” The Lancet. Respiratory medicine (2025). PMID: 40651490 ↗

    L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  380. [380]

    Higginson IJ, Brown ST, Oluyase AO et al.. “Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial.” The Lancet. Respiratory medicine (2024). PMID: 39265600 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  381. [381]

    Albert RK, Connett J, Bailey WC et al.. “Azithromycin for prevention of exacerbations of COPD.” The New England journal of medicine (2011). PMID: 21864166 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  382. [382]

    Criner GJ, Celli BR, Brightling CE et al.. “Benralizumab for the Prevention of COPD Exacerbations.” The New England journal of medicine (2019). PMID: 31112385 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  383. [383]

    Gloeckl R, Spielmanns M, Stankeviciene A et al.. “Smartphone application-based pulmonary rehabilitation in COPD: a multicentre randomised controlled trial.” Thorax (2025). PMID: 39706685 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  384. [384]

    Brown SE, Wootton S, Dale MT et al.. “Mobile health pulmonary rehabilitation (m-PR): a randomised controlled equivalence trial.” Thorax (2026). PMID: 40992935 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  385. [385]

    Kohlbrenner D, Kuhn M, Manettas A et al.. “Low-load blood flow restriction strength training in patients with COPD: a randomised single-blind pilot study.” Thorax (2024). PMID: 38129116 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History
  386. [386]

    Shergis JL, Thien F, Worsnop CJ et al.. “12-month randomised controlled trial of ginseng extract for moderate COPD.” Thorax (2019). PMID: 30940771 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
  387. [387]

    Mathioudakis AG, Bate S, Chatzimavridou-Grigoriadou V et al.. “Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial.” Thorax (2026). PMID: 41402044 ↗

    L2RCTCited in: 7. Acute Management and Exacerbation Rescue
  388. [388]

    Mathioudakis AG, Higham A, Bate S et al.. “Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial.” Thorax (2025). PMID: 40350264 ↗

    L2RCTCited in: 7. Acute Management and Exacerbation Rescue
  389. [389]

    Alsulayyim AS, Alasmari AM, Price LC et al.. “Dietary nitrate supplementation enhances exercise capacity in WHO Group 3 pulmonary hypertension: a double-blind, placebo-controlled, randomised crossover study (EDEN-OX2).” Thorax (2025). PMID: 39922710 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications
  390. [390]

    Beauchamp MK, Nonoyama M, Goldstein RS et al.. “Interval versus continuous training in individuals with chronic obstructive pulmonary disease--a systematic review.” Thorax (2009). PMID: 19996334 ↗

    L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue
  391. [391]

    Ko FW, Tam W, Siu EHS et al.. “Effect of short-course exercise training on the frequency of exacerbations and physical activity in patients with COPD: A randomized controlled trial.” Respirology (Carlton, Vic.) (2020). PMID: 32542906 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  392. [392]

    Kjærgaard JL, Juhl CB, Lange P et al.. “Early pulmonary rehabilitation after acute exacerbation of COPD: a randomised controlled trial.” ERJ open research (2020). PMID: 32083113 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  393. [393]

    Celli BR, Barnes PJ. “Exacerbations of chronic obstructive pulmonary disease.” The European respiratory journal (2007). PMID: 17540785 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 10. Complications
  394. [394]

    Garrod R, Malerba M, Crisafulli E. “Determinants of success.” The European respiratory journal (2011). PMID: 22045787 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  395. [395]

    Chaouat A, Naeije R, Weitzenblum E. “Pulmonary hypertension in COPD.” The European respiratory journal (2008). PMID: 18978137 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 10. Complications
  396. [396]

    Barnes PJ. “Corticosteroid effects on cell signalling.” The European respiratory journal (2006). PMID: 16452600 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue
  397. [397]

    Mannheimer S, Fors A, Holst A et al.. “Remote person-centred care and long-term medication management in primary care: post hoc analysis of a randomised controlled trial.” BMJ open (2026). PMID: 42386302 ↗

    L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  398. [398]

    Lapanan C, Schreiber AF, Wongtirawit N et al.. “The effects of asymmetrical versus symmetrical high-flow nasal cannula on respiratory muscle activity in acute hypoxaemic respiratory failure and chronic obstructive pulmonary disease: A randomised crossover study.” Pulmonology (2026). PMID: 42345563 ↗

    L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications
  399. [399]

    McLean S, Nurmatov U, Liu JL et al.. “Telehealthcare for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2011). PMID: 21735417 ↗

    L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue
  400. [400]

    Burge AT, Cox NS, Abramson MJ et al.. “Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2020). PMID: 32297320 ↗

    L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  401. [401]

    Uronis H, McCrory DC, Samsa G et al.. “Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2011). PMID: 21678356 ↗

    L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
  402. [402]

    Karner C, Cates CJ. “The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2011). PMID: 21901729 ↗

    L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue
  403. [403]

    Miao C, Feng S, Wang F et al.. “Quantitative CT-Derived extrapulmonary body composition and the risk of acute exacerbations in COPD: A prospective cohort study.” Respiratory medicine (2026). PMID: 42362120 ↗

    L2COHORTCited in: 7. Acute Management and Exacerbation Rescue
  404. [404]

    He C, Zou H, Jiang Z et al.. “Metagenomic Next-Generation Sequencing for Pulmonary Tuberculosis Diagnosis and Infection Risk Factor Analysis in AECOPD Patients: A Single-Center Retrospective Study.” Journal of clinical medicine (2026). PMID: 42355677 ↗

    L3COHORTCited in: 7. Acute Management and Exacerbation Rescue
  405. [405]

    Dehondt V, Kint N, Vanfleteren LE et al.. “Nutritional anemia is associated with increased risk of severe COPD exacerbations: a prospective cohort study.” The American journal of clinical nutrition (2026). PMID: 42323163 ↗

    L2COHORTCited in: 7. Acute Management and Exacerbation Rescue
  406. [406]

    Alison JA, McKeough ZJ, Johnston K et al.. “Australian and New Zealand Pulmonary Rehabilitation Guidelines.” Respirology (Carlton, Vic.) (2017). PMID: 28339144 ↗

    L1OTHERCited in: 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History
  407. [407]

    Suh ES, Murphy PB, Hart N. “Home mechanical ventilation for chronic obstructive pulmonary disease: What next after the HOT-HMV trial?” Respirology (Carlton, Vic.) (2019). PMID: 30729638 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 10. Complications
  408. [408]

    Maddocks M, Kon SS, Singh SJ et al.. “Rehabilitation following hospitalization in patients with COPD: can it reduce readmissions?” Respirology (Carlton, Vic.) (2014). PMID: 25529496 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue
  409. [409]

    Gao W, Li L, Wang Y et al.. “Bronchial epithelial cells: The key effector cells in the pathogenesis of chronic obstructive pulmonary disease?” Respirology (Carlton, Vic.) (2015). PMID: 25868842 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue
  410. [410]

    McSharry DG, Ryan S, Calverley P et al.. “Sleep quality in chronic obstructive pulmonary disease.” Respirology (Carlton, Vic.) (2012). PMID: 22758620 ↗

    L3OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
  411. [411]

    Tsubouchi K, Kotetsu Y, Takano T et al.. “Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema.” Respirology (Carlton, Vic.) (2026). PMID: 42417564 ↗

    L2OTHERCited in: 7. Acute Management and Exacerbation Rescue
  412. [412]

    Dreher M, Kabitz HJ. “Impact of obesity on exercise performance and pulmonary rehabilitation.” Respirology (Carlton, Vic.) (2012). PMID: 22348704 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue
  413. [413]

    Coleman JM, Wolfe LF, Kalhan R. “Noninvasive Ventilation in Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2019). PMID: 31185181 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  414. [414]

    Attaway AH, Mehra R, Zein JG et al.. “Nocturnal Hypoxemia Is Associated with Sarcopenia in Patients with Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2024). PMID: 38843487 ↗

    L3OTHERCited in: 7. Acute Management and Exacerbation Rescue
  415. [415]

    Marin JM, Soriano JB, Marin-Oto M et al.. “Sleep-disordered Breathing in Patients with Chronic Obstructive Pulmonary Disease: Prevalence and Outcomes.” Annals of the American Thoracic Society (2025). PMID: 40208311 ↗

    L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment
  416. [416]

    Clark KP, Degenholtz HB, Lindell KO et al.. “Supplemental Oxygen Therapy in Interstitial Lung Disease: A Narrative Review.” Annals of the American Thoracic Society (2023). PMID: 37590496 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue
  417. [417]

    Mehta AB, Douglas IS, Walkey AJ. “Evidence-based Utilization of Noninvasive Ventilation and Patient Outcomes.” Annals of the American Thoracic Society (2017). PMID: 28541747 ↗

    L3OTHERCited in: 7. Acute Management and Exacerbation Rescue
  418. [418]

    Paolillo S, Agostoni P. “Prognostic Role of Cardiopulmonary Exercise Testing in Clinical Practice.” Annals of the American Thoracic Society (2017). PMID: 28362512 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue
  419. [419]

    Walkey AJ, Wiener RS. “Use of noninvasive ventilation in patients with acute respiratory failure, 2000-2009: a population-based study.” Annals of the American Thoracic Society (2013). PMID: 23509327 ↗

    L3OTHERCited in: 7. Acute Management and Exacerbation Rescue
  420. [420]

    Su A, Xu Y, Han X et al.. “Association between serum uric acid levels and COPD: a meta-analysis and mendelian randomization study.” BMC pulmonary medicine (2026). PMID: 42426726 ↗

    L3SR_OBSCited in: 7. Acute Management and Exacerbation Rescue
  421. [421]

    Duiverman ML. “Noninvasive ventilation in stable hypercapnic COPD: what is the evidence?” ERJ open research (2018). PMID: 29637078 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications
  422. [422]

    Smallwood N, Thompson M, Warrender-Sparkes M et al.. “Integrated respiratory and palliative care may improve outcomes in advanced lung disease.” ERJ open research (2018). PMID: 29707561 ↗

    L4OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  423. [423]

    van Dijk M, Gan CT, Koster TD et al.. “Treatment of severe stable COPD: the multidimensional approach of treatable traits.” ERJ open research (2020). PMID: 32984420 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  424. [424]

    Finney LJ, Padmanaban V, Todd S et al.. “Validity of the diagnosis of pneumonia in hospitalised patients with COPD.” ERJ open research (2019). PMID: 31249841 ↗

    L3OTHERCited in: 7. Acute Management and Exacerbation Rescue
  425. [425]

    Kantorowski A, Wan ES, Homsy D et al.. “Determinants and outcomes of change in physical activity in COPD.” ERJ open research (2018). PMID: 30083551 ↗

    L3OTHERCited in: 7. Acute Management and Exacerbation Rescue
  426. [426]

    Dransfield MT, Voelker H, Bhatt SP et al.. “Metoprolol for the Prevention of Acute Exacerbations of COPD.” The New England journal of medicine (2019). PMID: 31633896 ↗

    L1RCTCited in: 8. Long-term and Definitive Management
  427. [427]

    Muiser S, Imkamp K, Seigers D et al.. “Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD.” Thorax (2023). PMID: 36725331 ↗

    L1RCTCited in: 8. Long-term and Definitive Management
  428. [428]

    Kofod LM, Hansen EF, Brocki BC et al.. “Optimised oxygenation improves functional capacity during daily activities in patients with COPD on long-term oxygen therapy: a randomised crossover trial.” Thorax (2025). PMID: 40473413 ↗

    L1RCTCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  429. [429]

    Bui DS, Lodge CJ, Burgess JA et al.. “Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life.” The Lancet. Respiratory medicine (2018). PMID: 29628376 ↗

    L2COHORTCited in: 8. Long-term and Definitive Management
  430. [430]

    Hoogendoorn M, Feenstra TL, Hoogenveen RT et al.. “Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD.” Thorax (2010). PMID: 20685746 ↗

    L1SR_OBSCited in: 8. Long-term and Definitive Management, 13. Prevention, Screening & Surveillance
  431. [431]

    Pépin JL, Herquelot E, Denis H et al.. “Impact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models.” Thorax (2025). PMID: 40393719 ↗

    L2COHORTCited in: 8. Long-term and Definitive Management
  432. [432]

    Gosens R, Gross N. “The mode of action of anticholinergics in asthma.” The European respiratory journal (2018). PMID: 30115613 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  433. [433]

    Spagnolo P, Fabbri LM, Bush A. “Long-term macrolide treatment for chronic respiratory disease.” The European respiratory journal (2012). PMID: 23180583 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  434. [434]

    Lipworth B, Wedzicha J, Devereux G et al.. “Beta-blockers in COPD: time for reappraisal.” The European respiratory journal (2016). PMID: 27390282 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  435. [435]

    Cazzola M, Matera MG. “Emerging inhaled bronchodilators: an update.” The European respiratory journal (2009). PMID: 19720811 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  436. [436]

    Agusti A, Fabbri LM, Singh D et al.. “Inhaled corticosteroids in COPD: friend or foe?” The European respiratory journal (2018). PMID: 30190269 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, History and Evolution of Treatment
  437. [437]

    Martin RJ, Bel EH, Pavord ID et al.. “Defining severe obstructive lung disease in the biologic era: an endotype-based approach.” The European respiratory journal (2019). PMID: 31515397 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  438. [438]

    Crosbie PA, Woodhead MA. “Long-term macrolide therapy in chronic inflammatory airway diseases.” The European respiratory journal (2009). PMID: 19118228 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  439. [439]

    Ernst P, Saad N, Suissa S. “Inhaled corticosteroids in COPD: the clinical evidence.” The European respiratory journal (2014). PMID: 25537556 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  440. [440]

    Albert P, Calverley PM. “Drugs (including oxygen) in severe COPD.” The European respiratory journal (2008). PMID: 18448506 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  441. [441]

    Yang X, Chen X, Yang C et al.. “Comparative effectiveness of different inhaler technique education modalities on clinical outcomes in patients with asthma and chronic obstructive pulmonary disease: a protocol for a systematic review and network meta-analysis of randomised controlled trials.” BMJ open (2026). PMID: 42315263 ↗

    L5SR_MA_RCTCited in: 8. Long-term and Definitive Management
  442. [442]

    Hansson A, Friberg M, Rankin G et al.. “Bronchial mucosal nuclear transcription factor expression and inflammatory response in humans after exposure to wood smoke.” Particle and fibre toxicology (2026). PMID: 42286681 ↗

    L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  443. [443]

    McDonough JE, Yuan R, Suzuki M et al.. “Small-airway obstruction and emphysema in chronic obstructive pulmonary disease.” The New England journal of medicine (2011). PMID: 22029978 ↗

    L4OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  444. [444]

    Khor YH, Palm A, Wong AW et al.. “Effects of long-term oxygen therapy on acute exacerbation and hospital burden: the national DISCOVERY study.” Thorax (2025). PMID: 40113248 ↗

    L2OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  445. [445]

    Kwok WC, Pates K, Shah A et al.. “Antimicrobial resistance in chronic lung infection: the road to resistance.” Thorax (2026). PMID: 40623822 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  446. [446]

    Park Y, Kim DK, Kim WJ et al.. “Effect of post-discharge transitional care in patients with COPD: a multicenter single-blind randomised controlled trial.” BMC pulmonary medicine (2026). PMID: 42298514 ↗

    L1RCTCited in: 8. Long-term and Definitive Management
  447. [447]

    Gutiérrez-Villegas C, Herrero-Montes M, Fernández Cacho LM et al.. “Global Economic and Social Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review (2020-2024).” International journal of chronic obstructive pulmonary disease (2026). PMID: 42292532 ↗

    L2SR_OBSCited in: 8. Long-term and Definitive Management
  448. [448]

    McNamara RJ, Epsley C, Coren E et al.. “Singing for adults with chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2017). PMID: 29253921 ↗

    L1SR_OBSCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  449. [449]

    Janjua S, Pike KC, Carr R et al.. “Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2021). PMID: 34496032 ↗

    L1SR_OBSCited in: 8. Long-term and Definitive Management
  450. [450]

    Yang IA, Clarke MS, Sim EH et al.. “Inhaled corticosteroids for stable chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2012). PMID: 22786484 ↗

    L1SR_OBSCited in: 8. Long-term and Definitive Management
  451. [451]

    Yang IA, Fong KM, Sim EH et al.. “Inhaled corticosteroids for stable chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2007). PMID: 17443520 ↗

    L1SR_OBSCited in: 8. Long-term and Definitive Management
  452. [452]

    Deng X, Xu L, Chen L et al.. “Safety and antibody responses to inactivated COVID-19 vaccines among elderly patients with COPD: a prospective cohort study.” Frontiers in immunology (2026). PMID: 42367765 ↗

    L2COHORTCited in: 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy
  453. [453]

    Mulhall P, Criner G. “Non-pharmacological treatments for COPD.” Respirology (Carlton, Vic.) (2016). PMID: 27099216 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
  454. [454]

    Wagner PD. “Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy?” Respirology (Carlton, Vic.) (2006). PMID: 17052294 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  455. [455]

    Chen L, A Hoefel G, Pathinayake PS et al.. “Inflammation-induced loss of CFTR-expressing airway ionocytes in non-eosinophilic asthma.” Respirology (Carlton, Vic.) (2024). PMID: 39358991 ↗

    L4OTHERCited in: 8. Long-term and Definitive Management
  456. [456]

    Spencer LM, McKeough ZJ. “Maintaining the benefits following pulmonary rehabilitation: Achievable or not?” Respirology (Carlton, Vic.) (2019). PMID: 30891887 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  457. [457]

    Rhee CK, Ko FWS, Giap VV et al.. “Management of COPD With Cardiovascular Risk in Asia: A Review by the Asian Pacific Society of Respirology COPD Assembly.” Respirology (Carlton, Vic.) (2025). PMID: 40785398 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 13. Prevention, Screening & Surveillance
  458. [458]

    Calverley P, Vlies B. “A rational approach to single, dual and triple therapy in COPD.” Respirology (Carlton, Vic.) (2015). PMID: 26611377 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  459. [459]

    Leong P, Osadnik CR, King PT et al.. “Right ventricular end-diastolic volume and outcomes in exacerbations of COPD.” Respirology (Carlton, Vic.) (2021). PMID: 34693587 ↗

    L2OTHERCited in: 8. Long-term and Definitive Management
  460. [460]

    Brusselle G, Bracke K. “Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease.” Annals of the American Thoracic Society (2014). PMID: 25525740 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  461. [461]

    Wedzicha JA. “Mechanisms of Chronic Obstructive Pulmonary Disease Exacerbations.” Annals of the American Thoracic Society (2015). PMID: 26595732 ↗

    L5OTHERCited in: 8. Long-term and Definitive Management, 13. Prevention, Screening & Surveillance
  462. [462]

    Wedzicha JA. “Mechanisms of Chronic Obstructive Pulmonary Disease Exacerbations.” Annals of the American Thoracic Society (2015). PMID: 26599578 ↗

    L5OTHERCited in: 8. Long-term and Definitive Management, 13. Prevention, Screening & Surveillance
  463. [463]

    Bhatt SP, Balte PP, Schwartz JE et al.. “Pooled Cohort Probability Score for Subclinical Airflow Obstruction.” Annals of the American Thoracic Society (2022). PMID: 35176216 ↗

    L2OTHERCited in: 8. Long-term and Definitive Management, 13. Prevention, Screening & Surveillance
  464. [464]

    Tashkin DP. “Effects of marijuana smoking on the lung.” Annals of the American Thoracic Society (2013). PMID: 23802821 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management
  465. [465]

    Wong GW, Miravitlles M, Chisholm A et al.. “Respiratory guidelines--which real world?” Annals of the American Thoracic Society (2014). PMID: 24559026 ↗

    L5OTHERCited in: 8. Long-term and Definitive Management
  466. [466]

    Martin A, Shah D, Ndirangu K et al.. “Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial.” ERJ open research (2022). PMID: 35198630 ↗

    L2OTHERCited in: 8. Long-term and Definitive Management
  467. [467]

    Fenwick E, Martin A, Schroeder M et al.. “Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK.” ERJ open research (2021). PMID: 33778055 ↗

    L2OTHERCited in: 8. Long-term and Definitive Management
  468. [468]

    Halpin DMG, Birk R, Brealey N et al.. “Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses.” ERJ open research (2018). PMID: 29750142 ↗

    L1OTHERCited in: 8. Long-term and Definitive Management
  469. [469]

    Naya I, Compton C, Ismaila AS et al.. “Preventing clinically important deterioration with single-inhaler triple therapy in COPD.” ERJ open research (2018). PMID: 30302335 ↗

    L1OTHERCited in: 8. Long-term and Definitive Management
  470. [470]

    Vestbo J, Lange P. “Prevention of COPD exacerbations: medications and other controversies.” ERJ open research (2015). PMID: 27730132 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 11. Prognosis and Natural History
  471. [471]

    Keene SJ, Adab P, de Vries F et al.. “The stability of the ADO score among UK COPD patients from The Health Improvement Network.” ERJ open research (2020). PMID: 32055631 ↗

    L2OTHERCited in: 8. Long-term and Definitive Management
  472. [472]

    Haas F, Bevelaqua F, Levin N et al.. “Pentoxifylline improves pulmonary gas exchange.” Chest (1990). PMID: 2306966 ↗

    L1RCTCited in: History and Evolution of Treatment
  473. [473]

    Ries AL, Ellis B, Hawkins RW. “Upper extremity exercise training in chronic obstructive pulmonary disease.” Chest (1988). PMID: 3349825 ↗

    L1RCTCited in: History and Evolution of Treatment
  474. [474]

    Buist AS, Connett JE, Miller RD et al.. “Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants.” Chest (1993). PMID: 8404115 ↗

    L1RCTCited in: History and Evolution of Treatment
  475. [475]

    Goldstein S, Askanazi J, Weissman C et al.. “Energy expenditure in patients with chronic obstructive pulmonary disease.” Chest (1987). PMID: 3100146 ↗

    L1RCTCited in: History and Evolution of Treatment
  476. [476]

    Thomas P, Pugsley JA, Stewart JH. “Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease.” Chest (1992). PMID: 1729064 ↗

    L1RCTCited in: History and Evolution of Treatment
  477. [477]

    Kirsten DK, Wegner RE, Jörres RA et al.. “Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease.” Chest (1993). PMID: 8404175 ↗

    L2RCTCited in: History and Evolution of Treatment
  478. [478]

    Marvin PM, Baker BJ, Dutt AK et al.. “Physiologic effects of oral bronchodilators during rest and exercise in chronic obstructive pulmonary disease.” Chest (1983). PMID: 6641302 ↗

    L1RCTCited in: History and Evolution of Treatment
  479. [479]

    Ashutosh K, Dev G, Steele D. “Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease.” Chest (1995). PMID: 7813271 ↗

    L1RCTCited in: History and Evolution of Treatment
  480. [480]

    Barberà JA, Peinado VI, Santos S. “Pulmonary hypertension in chronic obstructive pulmonary disease.” The European respiratory journal (2003). PMID: 12765440 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  481. [481]

    Viegi G, Pistelli F, Sherrill DL et al.. “Definition, epidemiology and natural history of COPD.” The European respiratory journal (2007). PMID: 17978157 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
  482. [482]

    Vassilakopoulos T, Zakynthinos S, Roussos Ch. “Respiratory muscles and weaning failure.” The European respiratory journal (1996). PMID: 8947090 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  483. [483]

    Blasi F. “Atypical pathogens and respiratory tract infections.” The European respiratory journal (2004). PMID: 15293621 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  484. [484]

    Bishop JA, Spencer LM, Dwyer TJ et al.. “Effect of pulmonary rehabilitation duration on exercise capacity and health-related quality of life in people with chronic obstructive pulmonary disease (PuRe Duration Trial): A randomized controlled equivalence trial.” Respirology (Carlton, Vic.) (2024). PMID: 39228164 ↗

    L1RCTCited in: History and Evolution of Treatment
  485. [485]

    Kikuchi S, Imai H, Tani Y et al.. “Proton pump inhibitors for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2020). PMID: 32844430 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  486. [486]

    Ni H, Soe Z, Moe S. “Aclidinium bromide for stable chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2014). PMID: 25234126 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  487. [487]

    Walters JA, Walters EH, Wood-Baker R. “Oral corticosteroids for stable chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2005). PMID: 16034972 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  488. [488]

    De Coster DA, Jones M, Thakrar N. “Beclometasone for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2013). PMID: 24105424 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  489. [489]

    Poole P, Chong J, Cates CJ. “Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2015). PMID: 26222376 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  490. [490]

    Chong J, Karner C, Poole P. “Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2012). PMID: 22972134 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  491. [491]

    Chen S, Wen Z, Wang C et al.. “High-flow nasal cannula for acute respiratory failure: a bibliometric analysis of current trends and future directions.” Frontiers in medicine (2026). PMID: 42254411 ↗

    L5SR_OBSCited in: History and Evolution of Treatment, 10. Complications
  492. [492]

    . “Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective.” Respirology (Carlton, Vic.) (2005). PMID: 15691232 ↗

    L1REVIEW_NARRATIVECited in: History and Evolution of Treatment
  493. [493]

    Vestbo J, Lange P. “Natural history of COPD: Focusing on change in FEV1.” Respirology (Carlton, Vic.) (2015). PMID: 26176980 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  494. [494]

    Rankin NM, McWilliams A, Marshall HM. “Lung cancer screening implementation: Complexities and priorities.” Respirology (Carlton, Vic.) (2020). PMID: 33200529 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
  495. [495]

    Roche N, Huchon GJ. “Current issues in the management of chronic obstructive pulmonary diseases.” Respirology (Carlton, Vic.) (1997). PMID: 9400684 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  496. [496]

    Nici L, Bontly TD, Zuwallack R et al.. “Self-management in chronic obstructive pulmonary disease. Time for a paradigm shift?” Annals of the American Thoracic Society (2014). PMID: 24460443 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  497. [497]

    Tuder RM. “Bringing Light to Chronic Obstructive Pulmonary Disease Pathogenesis and Resilience.” Annals of the American Thoracic Society (2018). PMID: 30759011 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  498. [498]

    Diaz AA, Estépar RS, Washko GR. “Computed Tomographic Airway Morphology in Chronic Obstructive Pulmonary Disease. Remodeling or Innate Anatomy?” Annals of the American Thoracic Society (2016). PMID: 26562761 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  499. [499]

    Yang K, Chen D, Wang Y et al.. “COPD Patients with a High Exacerbation Risk: Baseline Data Analysis of a National Chinese Prospective Multi-Center Study of Quality Improvement Project.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42266895 ↗

    L2RCTCited in: History and Evolution of Treatment
  500. [500]

    Criner GJ, Watz H, Han MK et al.. “Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical Trials.” American journal of respiratory and critical care medicine (2026). PMID: 42265988 ↗

    L1TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  501. [501]

    Zheng Z, Tang X, Li W et al.. “Sociodemographic Determinants of Hospitalized Exacerbations in Exposure-Defined COPD Phenotypes: A Nationwide Prospective Cohort Study in China.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42281812 ↗

    L2COHORTCited in: History and Evolution of Treatment
  502. [502]

    Miranda M, Brown M, van Haren FMP et al.. “Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.” Lung (2026). PMID: 42384225 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  503. [503]

    Shukkoor AA, Turgeon RD, De Vera MA et al.. “Association of ischaemic stroke/TIA with subsequent oral anticoagulant adherence in patients with atrial fibrillation: a scoping review.” BMJ open (2026). PMID: 42331577 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  504. [504]

    Shah PL, Slebos DJ, Sue R et al.. “Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3).” American journal of respiratory and critical care medicine (2025). PMID: 40920914 ↗

    L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  505. [505]

    Maddocks M, Nolan CM, Man WD et al.. “Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial.” The Lancet. Respiratory medicine (2015). PMID: 26701362 ↗

    L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  506. [506]

    Gupta N, Pinto LM, Morogan A et al.. “The COPD assessment test: a systematic review.” The European respiratory journal (2014). PMID: 24993906 ↗

    L5SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  507. [507]

    Lacasse Y, Casaburi R, Sliwinski P et al.. “Home oxygen for moderate hypoxaemia in chronic obstructive pulmonary disease: a systematic review and meta-analysis.” The Lancet. Respiratory medicine (2022). PMID: 35817074 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  508. [508]

    Zhang T, Zhou R, Wang T et al.. “Effects of traditional mind-body movement therapy on chronic cardiopulmonary dyspnoea: a systematic review and meta-analysis.” Thorax (2022). PMID: 35483892 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  509. [509]

    Taylor D, Jenkins AR, Parrott K et al.. “Efficacy of unsupervised exercise in adults with obstructive lung disease: a systematic review and meta-analysis.” Thorax (2021). PMID: 33685962 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  510. [510]

    Loughran KJ, Atkinson G, Beauchamp MK et al.. “Balance impairment in individuals with COPD: a systematic review with meta-analysis.” Thorax (2020). PMID: 32409612 ↗

    L5SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  511. [511]

    Benzo R, Hoult J, McEvoy C et al.. “Promoting Chronic Obstructive Pulmonary Disease Wellness through Remote Monitoring and Health Coaching: A Clinical Trial.” Annals of the American Thoracic Society (2022). PMID: 35914215 ↗

    L2RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  512. [512]

    Alwadani F, Ellis PR, Newnham M et al.. “Pulmonary rehabilitation and quality of life in alpha-1 antitrypsin deficiency: findings from a retrospective cohort study.” Thorax (2025). PMID: 40967906 ↗

    L2COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  513. [513]

    Aldhahir AM, Aldabayan YS, Alqahtani JS et al.. “A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study.” ERJ open research (2021). PMID: 33816594 ↗

    L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  514. [514]

    Prieur G, Delorme M, Lebret M et al.. “Nasal High-Flow Therapy during Exercise in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2022). PMID: 34644515 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  515. [515]

    Singanayagam A, Schembri S, Chalmers JD. “Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease.” Annals of the American Thoracic Society (2013). PMID: 23607835 ↗

    L2SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  516. [516]

    Iftikhar IH, Schimmel M, Sardi A et al.. “Bronchoscopic Lung Volume Reduction with Valves and Coils. A Network Meta-analysis.” Annals of the American Thoracic Society (2020). PMID: 32574516 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  517. [517]

    Spruit MA, Pitta F, McAuley E et al.. “Pulmonary Rehabilitation and Physical Activity in Patients with Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2015). PMID: 26161676 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  518. [518]

    Lacasse Y, Tan AM, Maltais F et al.. “Home Oxygen in Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2018). PMID: 29547003 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  519. [519]

    Sulaiman I, Wu BG, Chung M et al.. “Lower Airway Dysbiosis Augments Lung Inflammatory Injury in Mild-to-Moderate Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2023). PMID: 37677136 ↗

    L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 13. Prevention, Screening & Surveillance
  520. [520]

    Jones AW, Taylor A, Gowler H et al.. “Systematic review of interventions to improve patient uptake and completion of pulmonary rehabilitation in COPD.” ERJ open research (2017). PMID: 28154821 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  521. [521]

    Walters EH, Reid DW, Johns DP et al.. “Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling.” The European respiratory journal (2007). PMID: 17766634 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 13. Prevention, Screening & Surveillance
  522. [522]

    Neder JA, Berton DC, Arbex FF et al.. “Physiological and clinical relevance of exercise ventilatory efficiency in COPD.” The European respiratory journal (2017). PMID: 28275174 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  523. [523]

    Rowan SC, Keane MP, Gaine S et al.. “Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways.” The Lancet. Respiratory medicine (2016). PMID: 26895650 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications
  524. [524]

    Han MK, Martinez CH, Au DH et al.. “Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective.” The Lancet. Respiratory medicine (2016). PMID: 27185520 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  525. [525]

    Koo HK, Vasilescu DM, Booth S et al.. “Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study.” The Lancet. Respiratory medicine (2018). PMID: 30072106 ↗

    L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  526. [526]

    Kon SS, Canavan JL, Jones SE et al.. “Minimum clinically important difference for the COPD Assessment Test: a prospective analysis.” The Lancet. Respiratory medicine (2014). PMID: 24621681 ↗

    L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  527. [527]

    Zeng H, Ran H, Wang Y et al.. “Severity-Stratified Pulmonary Rehabilitation Modulates Diaphragm Function and Oxidative Stress in Hospitalized AECOPD Patients: A Randomized Controlled Trial.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42110507 ↗

    L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  528. [528]

    Shah PL, Herth FJ. “Current status of bronchoscopic lung volume reduction with endobronchial valves.” Thorax (2013). PMID: 24008689 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  529. [529]

    Zhang BB, Li CF, Fan HY. “Respiratory-Endocrinology Multidisciplinary Co-Management Pathway in Hospitalized Patients with ECOPD and Diabetes: A Randomized Controlled Trial.” COPD (2026). PMID: 42186793 ↗

    L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  530. [530]

    Pehlivan E, Özcan ZB, Karaahmetoğlu FS et al.. “Chair-based versus standard home exercise programs in people with COPD: A randomized controlled trial.” Heart & lung : the journal of critical care (2026). PMID: 42143500 ↗

    L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  531. [531]

    Petry Moecke DM, Gill BK, Zawadiuk OM et al.. “Underrepresentation of Rural Populations in Tele-Pulmonary Rehabilitation Trials: A SYSTEMATIC REVIEW.” Journal of cardiopulmonary rehabilitation and prevention (2026). PMID: 42384581 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  532. [532]

    Luca Bamber J, Cook M, Cordier R et al.. “Telerehabilitation versus face-to-face pulmonary rehabilitation in COPD: A systematic review and meta-analysis of comparative outcomes and delivery characteristics.” Journal of telemedicine and telecare (2026). PMID: 42227853 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  533. [533]

    Lacasse Y, Goldstein R, Lasserson TJ et al.. “Pulmonary rehabilitation for chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2006). PMID: 17054186 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  534. [534]

    Puhan M, Scharplatz M, Troosters T et al.. “Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2009). PMID: 19160250 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  535. [535]

    Osadnik CR, Singh S. “Pulmonary rehabilitation for obstructive lung disease.” Respirology (Carlton, Vic.) (2019). PMID: 31038835 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  536. [536]

    Troosters T, Blondeel A, Janssens W et al.. “The past, present and future of pulmonary rehabilitation.” Respirology (Carlton, Vic.) (2019). PMID: 30868699 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  537. [537]

    Vanfleteren LEGW, Gloeckl R. “Add-on interventions during pulmonary rehabilitation.” Respirology (Carlton, Vic.) (2019). PMID: 31115114 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  538. [538]

    Ibrahim W, Harvey-Dunstan TC, Greening NJ. “Rehabilitation in chronic respiratory diseases: In-hospital and post-exacerbation pulmonary rehabilitation.” Respirology (Carlton, Vic.) (2019). PMID: 30835884 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  539. [539]

    Bhatt SP, Westra J, Kuo YF et al.. “Pulmonary Rehabilitation Utilization in Older Adults with Chronic Obstructive Pulmonary Disease, 2013-2019.” Annals of the American Thoracic Society (2024). PMID: 38241014 ↗

    L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  540. [540]

    Blackstock FC, Lareau SC, Nici L et al.. “Chronic Obstructive Pulmonary Disease Education in Pulmonary Rehabilitation. An Official American Thoracic Society/Thoracic Society of Australia and New Zealand/Canadian Thoracic Society/British Thoracic Society Workshop Report.” Annals of the American Thoracic Society (2018). PMID: 29957038 ↗

    L1REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  541. [541]

    Ikonomou L, Wagner DE, Turner L et al.. “Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases.” Annals of the American Thoracic Society (2019). PMID: 30917290 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  542. [542]

    Spitzer KA, Stefan MS, Priya A et al.. “Promoting Participation in Pulmonary Rehabilitation after Hospitalization for Chronic Obstructive Pulmonary Disease, Strategies of Top-performing Systems: A Qualitative Study.” Annals of the American Thoracic Society (2023). PMID: 36449407 ↗

    L5REVIEW_NARRATIVECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  543. [543]

    Cheng Y, Yang H, Zheng L et al.. “Home-based pulmonary rehabilitation, hospital-based pulmonary rehabilitation, and standard care in chronic obstructive pulmonary disease patients-a systematic review and network meta-analysis.” Journal of thoracic disease (2026). PMID: 42182776 ↗

    L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  544. [544]

    Fawwad S, Makhlouf SSK, Mahgoub M et al.. “Long-Term Oxygen Therapy and Cognitive Function in Chronic Obstructive Pulmonary Disease: A Systematic Review.” Pulmonary medicine (2026). PMID: 42131994 ↗

    L2SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  545. [545]

    Cousins JL, Wood-Baker R, Wark PAB et al.. “Management of acute COPD exacerbations in Australia: do we follow the guidelines?” ERJ open research (2020). PMID: 32337215 ↗

    L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  546. [546]

    McNamara RJ, Elkins MR, Ferreira ML et al.. “Smallest worthwhile effect of land-based and water-based pulmonary rehabilitation for COPD.” ERJ open research (2015). PMID: 27730130 ↗

    L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  547. [547]

    Andrianopoulos V, Gloeckl R, Boensch M et al.. “Improvements in functional and cognitive status following short-term pulmonary rehabilitation in COPD lung transplant recipients: a pilot study.” ERJ open research (2019). PMID: 31544112 ↗

    L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  548. [548]

    Gloeckl R, Kenn K, Kroll D et al.. “Timely management of COPD exacerbations is associated with limited acute deterioration and early recovery: a prospective observational study.” Respiratory research (2026). PMID: 42432679 ↗

    L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
  549. [549]

    Bonniaud P, Fabre A, Frossard N et al.. “Optimising experimental research in respiratory diseases: an ERS statement.” The European respiratory journal (2018). PMID: 29773606 ↗

    L1GUIDELINECited in: 10. Complications
  550. [550]

    Matsuoka S, Washko GR, Yamashiro T et al.. “Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema.” American journal of respiratory and critical care medicine (2009). PMID: 19875683 ↗

    L4RCTCited in: 10. Complications
  551. [551]

    Goudie AR, Lipworth BJ, Hopkinson PJ et al.. “Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.” The Lancet. Respiratory medicine (2014). PMID: 24717626 ↗

    L1RCTCited in: 10. Complications
  552. [552]

    Andreas S, Testa M, Boyer L et al.. “Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.” The Lancet. Respiratory medicine (2022). PMID: 35026180 ↗

    L1RCTCited in: 10. Complications, 13. Prevention, Screening & Surveillance
  553. [553]

    Raghu G, Amatto VC, Behr J et al.. “Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.” The European respiratory journal (2015). PMID: 26424523 ↗

    L3SR_OBSCited in: 10. Complications
  554. [554]

    Duiverman ML, Wempe JB, Bladder G et al.. “Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD.” Thorax (2008). PMID: 18710905 ↗

    L1RCTCited in: 10. Complications
  555. [555]

    Lee KG, Hopkins M, Couban R et al.. “Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis.” The Lancet. Respiratory medicine (2026). PMID: 42034114 ↗

    L1SR_OBSCited in: 10. Complications
  556. [556]

    Maron BA, Brittain EL, Hess E et al.. “Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study.” The Lancet. Respiratory medicine (2020). PMID: 32730752 ↗

    L2COHORTCited in: 10. Complications
  557. [557]

    Schultze A, Walker AJ, MacKenna B et al.. “Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform.” The Lancet. Respiratory medicine (2020). PMID: 32979987 ↗

    L2COHORTCited in: 10. Complications
  558. [558]

    Bemand TJ, Chatoor R, Natale P et al.. “Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review.” Thorax (2023). PMID: 37217290 ↗

    L1SR_OBSCited in: 10. Complications
  559. [559]

    Smith TA, Davidson PM, Lam LT et al.. “The use of non-invasive ventilation for the relief of dyspnoea in exacerbations of chronic obstructive pulmonary disease; a systematic review.” Respirology (Carlton, Vic.) (2012). PMID: 22008176 ↗

    L1SR_OBSCited in: 10. Complications
  560. [560]

    Graul EL, Nordon C, Rhodes K et al.. “Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study.” American journal of respiratory and critical care medicine (2024). PMID: 38127850 ↗

    L2OTHERCited in: 10. Complications
  561. [561]

    Hoffmann J, Wilhelm J, Olschewski A et al.. “Microarray analysis in pulmonary hypertension.” The European respiratory journal (2016). PMID: 27076594 ↗

    L5REVIEW_NARRATIVECited in: 10. Complications
  562. [562]

    Wells JM, Washko GR, Han MK et al.. “Pulmonary arterial enlargement and acute exacerbations of COPD.” The New England journal of medicine (2012). PMID: 22938715 ↗

    L2OTHERCited in: 10. Complications
  563. [563]

    Lindenauer PK, Rothberg MB, Pekow PS et al.. “Outcomes of care by hospitalists, general internists, and family physicians.” The New England journal of medicine (2007). PMID: 18094379 ↗

    L2OTHERCited in: 10. Complications
  564. [564]

    Li X, Lai Y, Lane Z et al.. “Cigarette smoking is a secondary cause of folliculin loss.” Thorax (2022). PMID: 35301243 ↗

    L5OTHERCited in: 10. Complications
  565. [565]

    Balasubramanian A, Hemnes AR, Brittain EL et al.. “Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD.” Thorax (2026). PMID: 41309285 ↗

    L2OTHERCited in: 10. Complications
  566. [566]

    Lagravinese G, Santacesaria P, Castellana G et al.. “EEG patterns and cognitive outcomes in chronic respiratory disorders: a systematic review.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 42349048 ↗

    L3SR_OBSCited in: 10. Complications
  567. [567]

    Wu X, Zhang T, Yu T et al.. “Global research status and development trends of chronic obstructive pulmonary disease and gut microbiota: a comprehensive analysis based on bibliometrics and knowledge visualization.” Frontiers in microbiology (2026). PMID: 42317760 ↗

    L5SR_OBSCited in: 10. Complications
  568. [568]

    Herath SC, Normansell R, Maisey S et al.. “Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2018). PMID: 30376188 ↗

    L1SR_OBSCited in: 10. Complications, 12. Special Populations & Pregnancy
  569. [569]

    Walters JA, Tan DJ, White CJ et al.. “Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2014). PMID: 25178099 ↗

    L1SR_OBSCited in: 10. Complications
  570. [570]

    Walters JA, Gibson PG, Wood-Baker R et al.. “Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2009). PMID: 19160195 ↗

    L1SR_OBSCited in: 10. Complications
  571. [571]

    Sliwka A, Jankowski M, Gross-Sondej I et al.. “Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2018). PMID: 30141826 ↗

    L1SR_OBSCited in: 10. Complications
  572. [572]

    Simon ST, Higginson IJ, Booth S et al.. “Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults.” The Cochrane database of systematic reviews (2010). PMID: 20091630 ↗

    L1SR_OBSCited in: 10. Complications
  573. [573]

    Hillman D, Singh B, McArdle N et al.. “Relationships between ventilatory impairment, sleep hypoventilation and type 2 respiratory failure.” Respirology (Carlton, Vic.) (2014). PMID: 25219542 ↗

    L5REVIEW_NARRATIVECited in: 10. Complications
  574. [574]

    Calligaro GL, Gray DM. “Lung function abnormalities in HIV-infected adults and children.” Respirology (Carlton, Vic.) (2014). PMID: 25251876 ↗

    L5REVIEW_NARRATIVECited in: 10. Complications
  575. [575]

    Murphy PB, Suh ES, Hart N. “Non-invasive ventilation for obese patients with chronic respiratory failure: Are two pressures always better than one?” Respirology (Carlton, Vic.) (2019). PMID: 31121638 ↗

    L5REVIEW_NARRATIVECited in: 10. Complications
  576. [576]

    Weissmann N. “Chronic Obstructive Pulmonary Disease and Pulmonary Vascular Disease. A Comorbidity?” Annals of the American Thoracic Society (2018). PMID: 30759003 ↗

    L5REVIEW_NARRATIVECited in: 10. Complications
  577. [577]

    Mizumura K, Cloonan S, Choi ME et al.. “Autophagy: Friend or Foe in Lung Disease?” Annals of the American Thoracic Society (2016). PMID: 27027951 ↗

    L5REVIEW_NARRATIVECited in: 10. Complications, 11. Prognosis and Natural History
  578. [578]

    Wu Y, Wu N, Gao L. “Association of triglyceride-glucose index and triglyceride-glucose body mass index with risk and prognosis of chronic obstructive pulmonary disease: a systematic review and meta-analysis.” Journal of thoracic disease (2026). PMID: 42306697 ↗

    L1SR_OBSCited in: 10. Complications
  579. [579]

    Tsai H, Lee J, Hedlin H et al.. “Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011.” ERJ open research (2019). PMID: 31637253 ↗

    L3OTHERCited in: 10. Complications
  580. [580]

    Gäbler M, Ohrenberger G, Funk GC. “Treatment decisions in end-stage COPD: who decides how? A cross-sectional survey of different medical specialties.” ERJ open research (2019). PMID: 31544110 ↗

    L4OTHERCited in: 10. Complications
  581. [581]

    Vestbo J, Leather D, Diar Bakerly N et al.. “Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.” The New England journal of medicine (2016). PMID: 27593504 ↗

    L1RCTCited in: 11. Prognosis and Natural History
  582. [582]

    Albert RK, Au DH, Blackford AL et al.. “A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.” The New England journal of medicine (2016). PMID: 27783918 ↗

    L1RCTCited in: 11. Prognosis and Natural History
  583. [583]

    Zeng BY, Hsu CW, Hung CM et al.. “Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.” EClinicalMedicine (2026). PMID: 42376494 ↗

    L1SR_OBSCited in: 11. Prognosis and Natural History
  584. [584]

    Cherian M, Jensen D, Tan WC et al.. “Dyspnoea and symptom burden in mild-moderate COPD: the Canadian Cohort Obstructive Lung Disease Study.” ERJ open research (2021). PMID: 33898621 ↗

    L2OTHERCited in: 11. Prognosis and Natural History
  585. [585]

    Esteban C, Arostegui I, Aramburu A et al.. “Changes in health-related quality of life as a marker in the prognosis in COPD patients.” ERJ open research (2022). PMID: 35036422 ↗

    L2OTHERCited in: 11. Prognosis and Natural History
  586. [586]

    Dransfield MT, Nahm MH, Han MK et al.. “Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.” American journal of respiratory and critical care medicine (2009). PMID: 19556517 ↗

    L1RCTCited in: 12. Special Populations & Pregnancy
  587. [587]

    Deacon SJ, Vincent EE, Greenhaff PL et al.. “Randomized controlled trial of dietary creatine as an adjunct therapy to physical training in chronic obstructive pulmonary disease.” American journal of respiratory and critical care medicine (2008). PMID: 18420964 ↗

    L1RCTCited in: 12. Special Populations & Pregnancy
  588. [588]

    Bertens LC, Reitsma JB, van Mourik Y et al.. “COPD detected with screening: impact on patient management and prognosis.” The European respiratory journal (2014). PMID: 24925924 ↗

    L2RCTCited in: 12. Special Populations & Pregnancy
  589. [589]

    Wedzicha JA, Decramer M, Ficker JH et al.. “Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.” The Lancet. Respiratory medicine (2013). PMID: 24429126 ↗

    L1RCTCited in: 12. Special Populations & Pregnancy
  590. [590]

    Vogelmeier CF, Bateman ED, Pallante J et al.. “Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.” The Lancet. Respiratory medicine (2012). PMID: 24321804 ↗

    L1RCTCited in: 12. Special Populations & Pregnancy
  591. [591]

    Bui DS, Perret JL, Walters EH et al.. “Association between very to moderate preterm births, lung function deficits, and COPD at age 53 years: analysis of a prospective cohort study.” The Lancet. Respiratory medicine (2022). PMID: 35189074 ↗

    L2COHORTCited in: 12. Special Populations & Pregnancy
  592. [592]

    Martins RT, Currow DC, Abernethy AP et al.. “Effects of low-dose morphine on perceived sleep quality in patients with refractory breathlessness: A hypothesis generating study.” Respirology (Carlton, Vic.) (2015). PMID: 26560987 ↗

    L1RCTCited in: 12. Special Populations & Pregnancy
  593. [593]

    van der Molen MC, Hartman JE, Vermeulen CJ et al.. “Determinants of Lung Fissure Completeness.” American journal of respiratory and critical care medicine (2021). PMID: 34126038 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  594. [594]

    Janssens W, Lehouck A, Carremans C et al.. “Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act.” American journal of respiratory and critical care medicine (2009). PMID: 19164701 ↗

    L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
  595. [595]

    Raviv S, Hawkins KA, DeCamp MM et al.. “Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes.” American journal of respiratory and critical care medicine (2010). PMID: 21177883 ↗

    L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy, 13. Prevention, Screening & Surveillance
  596. [596]

    Yu W, Thurston GD. “Reductions in Respiratory Hospital Visits after a Coal Coking Plant Closure: A Natural Experiment.” American journal of respiratory and critical care medicine (2025). PMID: 40691837 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  597. [597]

    Lahousse L, Vernooij MW, Darweesh SK et al.. “Chronic obstructive pulmonary disease and cerebral microbleeds. The Rotterdam Study.” American journal of respiratory and critical care medicine (2013). PMID: 23885754 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  598. [598]

    Zhong N, Wang C, Yao W et al.. “Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey.” American journal of respiratory and critical care medicine (2007). PMID: 17575095 ↗

    L4OTHERCited in: 12. Special Populations & Pregnancy
  599. [599]

    Winthrop KL, McNelley E, Kendall B et al.. “Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease.” American journal of respiratory and critical care medicine (2010). PMID: 20508209 ↗

    L4OTHERCited in: 12. Special Populations & Pregnancy
  600. [600]

    Ernst P, Gonzalez AV, Brassard P et al.. “Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia.” American journal of respiratory and critical care medicine (2007). PMID: 17400730 ↗

    L3OTHERCited in: 12. Special Populations & Pregnancy
  601. [601]

    MacNee W, Rabinovich RA, Choudhury G. “Ageing and the border between health and disease.” The European respiratory journal (2014). PMID: 25323246 ↗

    L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
  602. [602]

    Barnes PJ. “Mechanisms of development of multimorbidity in the elderly.” The European respiratory journal (2015). PMID: 25614163 ↗

    L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
  603. [603]

    Soriano JB, Polverino F, Cosio BG. “What is early COPD and why is it important?” The European respiratory journal (2018). PMID: 30309976 ↗

    L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
  604. [604]

    Faner R, Cruz T, López-Giraldo A et al.. “Network medicine, multimorbidity and the lung in the elderly.” The European respiratory journal (2014). PMID: 25063242 ↗

    L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
  605. [605]

    Lowes D, Al-Shair K, Newton PJ et al.. “Predictors of mortality in chronic pulmonary aspergillosis.” The European respiratory journal (2017). PMID: 28179437 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  606. [606]

    Ambrosino N, Vagheggini G. “Noninvasive positive pressure ventilation in the acute care setting: where are we?” The European respiratory journal (2008). PMID: 18378782 ↗

    L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy
  607. [607]

    Yende S, Waterer GW, Tolley EA et al.. “Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects.” Thorax (2005). PMID: 16284220 ↗

    L4OTHERCited in: 12. Special Populations & Pregnancy
  608. [608]

    Gonzalez AV, Suissa S, Ernst P. “Gender differences in survival following hospitalisation for COPD.” Thorax (2010). PMID: 21113016 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  609. [609]

    Mannino DM, Davis KJ. “Lung function decline and outcomes in an elderly population.” Thorax (2006). PMID: 16517577 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  610. [610]

    Halonen JI, Lanki T, Yli-Tuomi T et al.. “Urban air pollution, and asthma and COPD hospital emergency room visits.” Thorax (2008). PMID: 18267984 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  611. [611]

    Connolly MJ, Lowe D, Anstey K et al.. “Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: Effect of age related factors and service organisation.” Thorax (2006). PMID: 16928716 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  612. [612]

    Sliedrecht A, den Elzen WP, Verheij TJ et al.. “Incidence and predictive factors of lower respiratory tract infections among the very elderly in the general population. The Leiden 85-plus Study.” Thorax (2008). PMID: 18388206 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  613. [613]

    Poole PJ, Chacko E, Wood-Baker RW et al.. “Influenza vaccine for patients with chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2006). PMID: 16437444 ↗

    L1SR_OBSCited in: 12. Special Populations & Pregnancy, 13. Prevention, Screening & Surveillance
  614. [614]

    Kopsaftis Z, Wood-Baker R, Poole P. “Influenza vaccine for chronic obstructive pulmonary disease (COPD).” The Cochrane database of systematic reviews (2018). PMID: 29943802 ↗

    L1SR_OBSCited in: 12. Special Populations & Pregnancy, 13. Prevention, Screening & Surveillance
  615. [615]

    Bayraktar YŞ, Uyar HG, Cebeci Y et al.. “The Relationship Between the Pan-Immune-Inflammation Value (PIV) and Mortality in Elderly Critically Ill Patients with Sepsis: A Single-Centre Retrospective Study.” Journal of clinical medicine (2026). PMID: 42194762 ↗

    L4COHORTCited in: 12. Special Populations & Pregnancy
  616. [616]

    Pu H, Liu L, Chang Y et al.. “Multicentre prospective cohort study to develop and validate a machine learning-based model for predicting 6-month all-cause mortality in elderly patients with advanced chronic obstructive pulmonary disease in China: study protocol.” BMJ open (2026). PMID: 42191200 ↗

    L5COHORTCited in: 12. Special Populations & Pregnancy
  617. [617]

    Liu W, Li Y, Chen X et al.. “Association between blood eosinophil count and in-hospital mortality among systemic corticosteroids-treated patients with COPD-bronchiectasis overlap: a retrospective cohort study.” Frontiers in pharmacology (2026). PMID: 42137338 ↗

    L2COHORTCited in: 12. Special Populations & Pregnancy
  618. [618]

    Al-Maisary S, Mustafi M, Romano G et al.. “Clinical Outcomes of Cardiac Implantable Electronic Device Infections in Octogenarians: A 20-Year Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42074797 ↗

    L2COHORTCited in: 12. Special Populations & Pregnancy
  619. [619]

    Li S, Zhao H, Zhang M et al.. “Long-term health outcomes in elderly COPD patients with long COVID: a 2-year prospective cohort study.” Respiratory research (2026). PMID: 42045916 ↗

    L2COHORTCited in: 12. Special Populations & Pregnancy
  620. [620]

    Çelik FH, Eren EE, Baykan N et al.. “Elderly patients with healthcare-associated infections in the emergency department: clinical characteristics and risk factors for septic shock: a retrospective study.” BMC geriatrics (2026). PMID: 42026516 ↗

    L4COHORTCited in: 12. Special Populations & Pregnancy
  621. [621]

    MacDonald MI, Polkinghorne KR, MacDonald CJ et al.. “Elevated blood lactate in COPD exacerbations associates with adverse clinical outcomes and signals excessive treatment with β2 -agonists.” Respirology (Carlton, Vic.) (2023). PMID: 37400102 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  622. [622]

    Shin B, Lee H, Kang D et al.. “Airflow limitation severity and post-operative pulmonary complications following extra-pulmonary surgery in COPD patients.” Respirology (Carlton, Vic.) (2017). PMID: 28117553 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  623. [623]

    Boschetto P, Fucili A, Stendardo M et al.. “Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure.” Respirology (Carlton, Vic.) (2013). PMID: 22985248 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  624. [624]

    Tsuda Y, Noguchi T, Mochizuki H et al.. “Patients with mild-to-moderate asthma may develop clinically significant chronic obstructive pulmonary disease.” Respirology (Carlton, Vic.) (2009). PMID: 19645870 ↗

    L3OTHERCited in: 12. Special Populations & Pregnancy
  625. [625]

    Zhong C, Tian Q, Wei J et al.. “Association of short-term exposure to PM1 with hospital admission from total and cause-specific respiratory diseases.” Respirology (Carlton, Vic.) (2024). PMID: 39622696 ↗

    L3OTHERCited in: 12. Special Populations & Pregnancy
  626. [626]

    Fruchter O, Yigla M. “Predictors of long-term survival in elderly patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease.” Respirology (Carlton, Vic.) (2008). PMID: 18811883 ↗

    L3OTHERCited in: 12. Special Populations & Pregnancy
  627. [627]

    Vozoris NT, Pequeno P, Li P et al.. “Predictors of Opioid-related Adverse Pulmonary Events among Older Adults with Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2020). PMID: 32396385 ↗

    L3OTHERCited in: 12. Special Populations & Pregnancy
  628. [628]

    Skloot GS, Busse PJ, Braman SS et al.. “An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly.” Annals of the American Thoracic Society (2016). PMID: 27831798 ↗

    L5OTHERCited in: 12. Special Populations & Pregnancy
  629. [629]

    Du Berry C, Mainzer RM, Westrupp N et al.. “The Effect of Being Born Moderate to Late Preterm on Lung Function and Respiratory Morbidity at 9 to 10 Years of Age.” Annals of the American Thoracic Society (2025). PMID: 39835933 ↗

    L2OTHERCited in: 12. Special Populations & Pregnancy
  630. [630]

    Martinez CH, Diaz AA, Meldrum CA et al.. “Handgrip Strength in Chronic Obstructive Pulmonary Disease. Associations with Acute Exacerbations and Body Composition.” Annals of the American Thoracic Society (2017). PMID: 29090990 ↗

    L4OTHERCited in: 12. Special Populations & Pregnancy
  631. [631]

    Baillargeon J, Singh G, Kuo YF et al.. “Association of Opioid and Benzodiazepine Use with Adverse Respiratory Events in Older Adults with Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2019). PMID: 31104504 ↗

    L3OTHERCited in: 12. Special Populations & Pregnancy
  632. [632]

    Rice MB, Henderson SB, Lambert AA et al.. “Respiratory Impacts of Wildland Fire Smoke: Future Challenges and Policy Opportunities. An Official American Thoracic Society Workshop Report.” Annals of the American Thoracic Society (2021). PMID: 33938390 ↗

    L5OTHERCited in: 12. Special Populations & Pregnancy
  633. [633]

    Date K, Antoniou E, Polkowska-Kramek A et al.. “The Global Burden of Human Metapneumovirus in High-Risk Adults: A Systematic Literature Review and Meta-Analysis.” Journal of epidemiology and global health (2026). PMID: 42126483 ↗

    L1SR_OBSCited in: 12. Special Populations & Pregnancy
  634. [634]

    Cleutjens FA, Pedone C, Janssen DJ et al.. “Sleep quality disturbances and cognitive functioning in elderly patients with COPD.” ERJ open research (2016). PMID: 27957482 ↗

    L4OTHERCited in: 12. Special Populations & Pregnancy
  635. [635]

    Jo T, Yasunaga H, Yamauchi Y et al.. “Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study.” ERJ open research (2020). PMID: 32039260 ↗

    L3OTHERCited in: 12. Special Populations & Pregnancy
  636. [636]

    Meteran H, Miller MR, Thomsen SF et al.. “The impact of different spirometric definitions on the prevalence of airway obstruction and their association with respiratory symptoms.” ERJ open research (2017). PMID: 29250530 ↗

    L4OTHERCited in: 12. Special Populations & Pregnancy
  637. [637]

    Vaillant G, Zappella N, Kantor E et al.. “Association Between Pre-Transplant Psoas Sarcopenia and Perioperative Outcomes in Lung Transplant Recipients: A Single-Centre Retrospective Cohort Study.” Interdisciplinary cardiovascular and thoracic surgery (2026). PMID: 42103920 ↗

    L3COHORTCited in: 12. Special Populations & Pregnancy
  638. [638]

    Quan S, Li S, Li S et al.. “Epidemiological characteristics and changing patterns of hospitalizations among middle-aged and elderly patients in Northwest China, 2020-2024: A retrospective cohort study.” SAGE open medicine (2026). PMID: 42079506 ↗

    L3COHORTCited in: 12. Special Populations & Pregnancy
  639. [639]

    Tardif A, Whitmore GA, Vandemheen KL et al.. “Patient Factors and Clinical Efficacy of Early Identification and Treatment of Chronic Obstructive Pulmonary Disease and Asthma.” American journal of respiratory and critical care medicine (2025). PMID: 41056133 ↗

    L4RCTCited in: 13. Prevention, Screening & Surveillance
  640. [640]

    Jordan RE, Adab P, Sitch A et al.. “Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial.” The Lancet. Respiratory medicine (2016). PMID: 27444687 ↗

    L1RCTCited in: 13. Prevention, Screening & Surveillance
  641. [641]

    Warnier MJ, van Riet EE, Rutten FH et al.. “Smoking cessation strategies in patients with COPD.” The European respiratory journal (2012). PMID: 22936706 ↗

    L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
  642. [642]

    Siedlinski M, Cho MH, Bakke P et al.. “Genome-wide association study of smoking behaviours in patients with COPD.” Thorax (2011). PMID: 21685187 ↗

    L4RCTCited in: 13. Prevention, Screening & Surveillance
  643. [643]

    Alfageme I, Vazquez R, Reyes N et al.. “Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.” Thorax (2005). PMID: 16227328 ↗

    L1RCTCited in: 13. Prevention, Screening & Surveillance
  644. [644]

    Prochaska J, Rubinstein M, Perdok R et al.. “Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials.” Thorax (2026). PMID: 40962497 ↗

    L2RCTCited in: 13. Prevention, Screening & Surveillance
  645. [645]

    Bischoff EW, Hamd DH, Sedeno M et al.. “Effects of written action plan adherence on COPD exacerbation recovery.” Thorax (2010). PMID: 21037270 ↗

    L2RCTCited in: 13. Prevention, Screening & Surveillance
  646. [646]

    Jones RC, Price D, Ryan D et al.. “Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort.” The Lancet. Respiratory medicine (2014). PMID: 24717623 ↗

    L3COHORTCited in: 13. Prevention, Screening & Surveillance
  647. [647]

    Qin R, Liu Z, Cheng AQ et al.. “Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD.” Respirology (Carlton, Vic.) (2024). PMID: 38494828 ↗

    L1RCTCited in: 13. Prevention, Screening & Surveillance
  648. [648]

    Zhou Z, Zhou A, Zhao Y et al.. “Evaluating the Clinical COPD Questionnaire: A systematic review.” Respirology (Carlton, Vic.) (2017). PMID: 28102972 ↗

    L2SR_OBSCited in: 13. Prevention, Screening & Surveillance
  649. [649]

    Gao YH, Guan WJ, Liu Q et al.. “Impact of COPD and emphysema on survival of patients with lung cancer: A meta-analysis of observational studies.” Respirology (Carlton, Vic.) (2015). PMID: 26567533 ↗

    L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
  650. [650]

    Konstantinidis I, Zou RH, Papageorgiou SN et al.. “Effect of Human Immunodeficiency Virus on Lung Function and Structure: A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2025). PMID: 39417747 ↗

    L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
  651. [651]

    Faiz A, Mahbub RM, Boedijono FS et al.. “IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels.” American journal of respiratory and critical care medicine (2023). PMID: 37708400 ↗

    L4OTHERCited in: 13. Prevention, Screening & Surveillance
  652. [652]

    Li Y, Wen F, Ma Q et al.. “Use of CAPTURE to Identify Individuals Who May or May Not Require Treatment for Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2023). PMID: 37315325 ↗

    L2OTHERCited in: 13. Prevention, Screening & Surveillance
  653. [653]

    Brehm JM, Celedón JC. “Chronic obstructive pulmonary disease in Hispanics.” American journal of respiratory and critical care medicine (2007). PMID: 18029789 ↗

    L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
  654. [654]

    Degens H, Gayan-Ramirez G, van Hees HW. “Smoking-induced skeletal muscle dysfunction: from evidence to mechanisms.” American journal of respiratory and critical care medicine (2015). PMID: 25581779 ↗

    L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
  655. [655]

    Regan EA, Lowe ME, Make BJ et al.. “Early Evidence of Chronic Obstructive Pulmonary Disease Obscured by Race-Specific Prediction Equations.” American journal of respiratory and critical care medicine (2024). PMID: 37611073 ↗

    L4OTHERCited in: 13. Prevention, Screening & Surveillance
  656. [656]

    Florman KEH, Siddharthan T, Pollard SL et al.. “Unmet Diagnostic and Therapeutic Opportunities for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Countries.” American journal of respiratory and critical care medicine (2023). PMID: 37369142 ↗

    L4OTHERCited in: 13. Prevention, Screening & Surveillance
  657. [657]

    Godtfredsen NS, Lam TH, Hansel TT et al.. “COPD-related morbidity and mortality after smoking cessation: status of the evidence.” The European respiratory journal (2008). PMID: 18827152 ↗

    L2REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
  658. [658]

    Kauczor HU, Bonomo L, Gaga M et al.. “ESR/ERS white paper on lung cancer screening.” The European respiratory journal (2015). PMID: 25929956 ↗

    L1OTHERCited in: 13. Prevention, Screening & Surveillance
  659. [659]

    Jiménez-Ruiz CA, Andreas S, Lewis KE et al.. “Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit.” The European respiratory journal (2015). PMID: 25882805 ↗

    L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
  660. [660]

    Bondonno NP, Parmenter BH, Dalgaard F et al.. “Flavonoid intakes inversely associate with COPD in smokers.” The European respiratory journal (2022). PMID: 35058251 ↗

    L2OTHERCited in: 13. Prevention, Screening & Surveillance
  661. [661]

    Michotte N, Demeure F, Guiot J et al.. “Optimizing COPD Care in Belgium: A Multidisciplinary Expert Consensus on Cardiopulmonary Risk Management.” International journal of chronic obstructive pulmonary disease (2026). PMID: 41939929 ↗

    L5GUIDELINECited in: 13. Prevention, Screening & Surveillance
  662. [662]

    Rigotti NA. “Smoking cessation in patients with respiratory disease: existing treatments and future directions.” The Lancet. Respiratory medicine (2013). PMID: 24429130 ↗

    L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
  663. [663]

    Thun MJ, Carter BD, Feskanich D et al.. “50-year trends in smoking-related mortality in the United States.” The New England journal of medicine (2013). PMID: 23343064 ↗

    L2OTHERCited in: 13. Prevention, Screening & Surveillance
  664. [664]

    Decramer M, Cooper CB. “Treatment of COPD: the sooner the better?” Thorax (2010). PMID: 20805184 ↗

    L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
  665. [665]

    Lapperre TS, Postma DS, Gosman MM et al.. “Relation between duration of smoking cessation and bronchial inflammation in COPD.” Thorax (2005). PMID: 16055612 ↗

    L4OTHERCited in: 13. Prevention, Screening & Surveillance
  666. [666]

    Jordan RE, Lam KB, Cheng KK et al.. “Case finding for chronic obstructive pulmonary disease: a model for optimising a targeted approach.” Thorax (2010). PMID: 20522845 ↗

    L4OTHERCited in: 13. Prevention, Screening & Surveillance
  667. [667]

    Kotz D, Viechtbauer W, Simpson CR et al.. “Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease.” Thorax (2017). PMID: 28473506 ↗

    L2OTHERCited in: 13. Prevention, Screening & Surveillance
  668. [668]

    Li Y, Kenmoe S, Begier E et al.. “Hospitalization Burden Estimates of Respiratory Syncytial Virus With Adjustment for Case Underascertainment in Adults Aged 18 to 65 Years in High-Income Countries: A Systematic Review, Meta-Analysis, and Modeling Study.” Open forum infectious diseases (2026). PMID: 42325648 ↗

    L2SR_OBSCited in: 13. Prevention, Screening & Surveillance
  669. [669]

    Heimbach NS, Ding J, Eidelman DH et al.. “Single cell RNA-sequencing meta-analysis identifies the molecular signature of smoking cessation on the human lung.” Translational research : the journal of laboratory and clinical medicine (2026). PMID: 42302895 ↗

    L4SR_OBSCited in: 13. Prevention, Screening & Surveillance
  670. [670]

    Du D, He S, Guo S et al.. “Performance of multiple case-finding approaches in detecting chronic obstructive pulmonary disease: a systematic review and network meta-analysis.” Public health (2026). PMID: 42214892 ↗

    L2SR_OBSCited in: 13. Prevention, Screening & Surveillance
  671. [671]

    Patel S, Marchant J, Bhatt SP et al.. “Rural versus urban living and COPD: a systematic review.” European respiratory review : an official journal of the European Respiratory Society (2026). PMID: 42055591 ↗

    L2SR_OBSCited in: 13. Prevention, Screening & Surveillance
  672. [672]

    Li X, Ma X, Qin W et al.. “Pharmacist-Led Integrated Management for Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.” International journal of chronic obstructive pulmonary disease (2026). PMID: 42021780 ↗

    L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
  673. [673]

    Gulati RR, Yaqub F, Goodman AL. “Enhancing uptake of respiratory vaccinations in asthma and chronic obstructive pulmonary disease (COPD) patients: a systematic review.” Vaccine (2026). PMID: 42000586 ↗

    L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
  674. [674]

    van Eerd EA, van der Meer RM, van Schayck OC et al.. “Smoking cessation for people with chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2016). PMID: 27545342 ↗

    L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
  675. [675]

    Walters JA, Tang JN, Poole P et al.. “Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.” The Cochrane database of systematic reviews (2017). PMID: 28116747 ↗

    L1SR_OBSCited in: 13. Prevention, Screening & Surveillance
  676. [676]

    Shiota A, Kan-O K, Ishii Y et al.. “Epigenetic Dysregulation of the NKX2-1/SPDEF Axis Drives Persistent Goblet Cell Differentiation and Epithelial Barrier Dysfunction in Chronic Obstructive Pulmonary Disease.” Respirology (Carlton, Vic.) (2026). PMID: 41559520 ↗

    L4OTHERCited in: 13. Prevention, Screening & Surveillance
  677. [677]

    Li Y, Zhang P, An Z et al.. “Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations.” Respirology (Carlton, Vic.) (2022). PMID: 35705329 ↗

    L2OTHERCited in: 13. Prevention, Screening & Surveillance
  678. [678]

    Drummond MB, Buist AS, Crapo JD et al.. “Chronic obstructive pulmonary disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.” Annals of the American Thoracic Society (2014). PMID: 24754824 ↗

    L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance
  679. [679]

    Reilly MJ, Timmer SJ, Rosenman KD. “The Burden of Silicosis in Michigan: 1988-2016.” Annals of the American Thoracic Society (2018). PMID: 30188758 ↗

    L4OTHERCited in: 13. Prevention, Screening & Surveillance
  680. [680]

    Hawkins NM, Peterson S, Ezzat AM et al.. “Control of Cardiovascular Risk Factors in Patients with Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2022). PMID: 35007497 ↗

    L2OTHERCited in: 13. Prevention, Screening & Surveillance
  681. [681]

    Tavakoli H, Chen W, Sin DD et al.. “Predicting Severe Chronic Obstructive Pulmonary Disease Exacerbations. Developing a Population Surveillance Approach with Administrative Data.” Annals of the American Thoracic Society (2020). PMID: 32383971 ↗

    L2OTHERCited in: 13. Prevention, Screening & Surveillance
  682. [682]

    Kunadian V, Wilson N, Stocken DD et al.. “Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial.” ERJ open research (2019). PMID: 31403053 ↗

    L1OTHERCited in: 13. Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…